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Lungenes nevroendokrine system 
 
- betydning ved fysiologiske og patologiske tilstander 
 
Nevroendokrine (NE) celler er en benevnelse på spesialiserte celler som finnes diffust utbredt i 
flere organ i kroppen og som har evnen til å produsere og skille ut hormon-liknende substanser. 
I lungene oppfattes ansamlinger av disse cellene som sanseorgan som monitorerer oksygen-
nivået, og de spiller sannsynligvis en viktig rolle for lungenes utvikling, regulering av 
lungesirkulasjon og luftstrøm, samt immunrespons.  
 
Hovedmålet med avhandlingen har vært å se på ulike sider ved lungenes NE system ved 
fysiologiske og patologiske tilstander, med fire delarbeider som hver for seg belyser ulike 
aspekt ved dette. 
 
I det første arbeidet ble den generelle NE markøren kromogranin A (CgA) målt i blodprøver fra 
personer som deltok i Helseundersøkelsen i Nord-Trøndelag (HUNT 1995-97). Resultatene 
viste at mannlige deltakere med dårlig lungefunksjon hadde høyere nivå av CgA enn deltakere 
med normal lungefunksjon, som et uttrykk for NE aktivering. 
 
Det andre arbeidet omhandler et 72 ukers eksponerings-forsøk med inhalasjon av karbon 
monoksid (CO) hos rotter gitt i konsentrasjoner som tilsvarer blod-verdier hos stor-røykere. 
Bortsett fra forstørret hjerte, ble det ikke funnet andre røyke-relaterte skader på hjerte/kar-
systemet eller lungene. CO hadde ingen effekt på svulstforekomst eller forandringer i antall NE 
celler. 
 
I det tredje arbeidet ble ulike NE markører undersøkt med immunhistokjemiske, 
immunelektronmikroskopiske og biokjemiske metoder hos pasienter med ikke-småcellet 
lungecancer. Hovedfunnet her var et større antall svulster positive for NE markører enn tidligere 
beskrevet når signalforsterkende teknikker ble brukt ved immunhistokjemi. Dette kan ha 
betydning for forståelsen av svulstenes biologi, og kan være uttrykk for at lungenes NE celler er 
opphavsceller for flere slike svulster enn tidligere antatt. 
 
Det siste delarbeidet belyser sekresjon av substanser fra lungenes NE system ved hypoksi i en 
isolert, ventilert og sirkulert rottelunge-modell. Ved lave oksygennivå falt konsentrasjonen av 
proteinet bombesin i buffer sirkulert gjennom lungekretsløpet. I tillegg ble det funnet øket antall 
immunmerkede celler med calcitonin gene-related peptide, noe som tyder på redusert cellulær 
utskillelse ved eksponering for hypoksi. Resultatene viser at hypoksi er assosiert med raske 
forandringer i lungenes NE system for å opprettholde en balansert ventilasjon og sirkulasjon. 
 
Samlet gir arbeidene økt kunnskap om det nevroendokrine system ved ulike sykdoms-prosesser 
som luftveisobstruksjon, inhalasjon av gasser som CO, i svulstutvikling og ved fysiologiske 
prosesser som hypoksi. 
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2. Summary 
 
Paper I 
Increased serum levels of chromogranin A in male smokers with airway obstruction. 
The neuroendocrine (NE) system may play an important role in smoking-induced 
airway diseases. The peptide chromogranin A (CgA), which is a general NE marker, 
was evaluated in sera from three study groups selected from the bronchial obstruction 
study (BONT) of the large cross-sectional Nord-Trøndelag Health Study (HUNT). The 
study groups included never-smokers with normal lung function, smokers with normal 
lung function and smokers with airway obstruction. The results showed that male 
smokers with airway obstruction had significant higher serum CgA than both smokers 
without airway obstruction and never-smokers with normal lung function. The elevated 
serum levels of CgA correlated with the degree of airway obstruction. Moreover, 
presence of respiratory symptoms and chronic bronchitis among male smokers were 
associated with increased serum CgA levels. Women had CgA levels similar to male 
smokers independent of smoking status and lung function. Elevated serum CgA levels 
in subjects with airway obstruction and respiratory symptoms may represent NE 
activation in inflammatory or remodelling processes in the lung.    
 
Paper II 
Chronic inhalation of carbon monoxide: Effects on the respiratory and cardiovascular 
system at doses corresponding to tobacco smoking. 
Long-term effects of low doses of carbon monoxide (CO), as in the gaseous component 
of tobacco smoke, are not well known. In paper II, the effects of chronic inhalation of 
CO on the respiratory and cardiovascular system at doses corresponding to tobacco 
smoking and its effect on tumourigenesis and pulmonary NE cells were evaluated in 
rats. In the cardiovascular system, only cardiac hypertrophy was observed. No signs of 
atherosclerosis were found. In the lungs, no signs of pathology similar to that associated 
with cigarette smoking were observed, and no differences in number of pulmonary NE 
cells were found between the exposure groups. In addition, no exposure related 
carcinogenic effects were observed. The results in paper II suggest that low dose CO 
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exposure is probably not responsible for the respiratory pathology associated with 
tobacco smoking, but may contribute to smoking-related cardiac pathology. 
 
Paper III 
Expression of neuroendocrine markers in non-small cell lung cancer. A biochemical, 
immunohistochemical and ultrastructural study. 
NE differentiation is reported in some cases of non-small cell lung cancer (NSCLC). In 
paper III, 20 cases of NSCLC were examined using immunohistochemical (IHC) 
methods with signal amplification technique and immunoelectron microscopy (IEM). In 
addition, circulating levels of the NE markers CgA and neuron-specific enolase (NSE) 
were measured. The results revealed that for some NE markers, a higher number of 
immunoreactive tumours than previously reported were identified with the use of a 
signal amplification technique. Furthermore, labelling of CgA in secretory granules 
using IEM was not found to be as sensitive as IHC methods in detecting NE features in 
NSCLC. Finally, no association between circulating levels of NE markers and IHC 
reactivity was observed. Knowing the expression of different NE markers may improve 
our understanding of the tumour biology and represent an important diagnostic tool for 
future targeted therapy of cancer.  
 
Paper IV 
Effects of intermittent alveolar hypoxia on the release of neuroendocrine products in 
isolated rat lung. 
Alveolar hypoxia is associated with several reactions in the lung, and the pulmonary NE 
system may play an important role in the homeostatic control. In paper IV, the effects of 
acute intermittent alveolar hypoxia on the release of NE products in isolated buffer-
perfused and ventilated rat lungs were examined. Perfusate collected from isolated rat 
lungs ventilated intermittently with hypoxic and normoxic gas was analysed for the 
bioactive NE products bombesin-like-peptides (BLPs) and serotonin. In lungs ventilated 
with intermittent hypoxia (IH), perfusate levels of BLPs decreased compared to lungs 
ventilated with normoxic gas only. No difference was observed in perfusate levels of 
serotonin between the two groups. At the end of the study, immunohistochemical 
evaluation of the lungs revealed significantly increased numbers of pulmonary NE cells 
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immunoreactive to calcitonin gene-related peptide (CGRP) in IH ventilated lungs, 
indicating diminished release of the neuropeptide during hypoxia. No difference was 
observed in the immunoreactivity for CgA between the groups. Together, these results 
suggest that intermittent periods of hypoxia are associated with a rapid physiological 
response in the pulmonary NE system probably in order to maintain a well balanced 
ventilation and perfusion relationship in the lung. 
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3.       Introduction 
 
3.1. The diffuse NE system - general aspects 
 
In most animal species, NE cells are found in several organs and systems, especially in 
the epithelial surfaces. They are scattered among other cells either as single cells or 
clusters of cells. Although these cells are not well defined anatomical entities or organs, 
they share several important functional and morphological properties. Collectively, they 
are named as “the diffuse neuroendocrine (or endocrine) system” (DNES) (Montuenga 
et al. 2003). In the nineteenth century, Heidenhain (1870) and Kultschitzky (1896) first 
described these cells as “clear cells” with basal granules in the epithelium of stomach 
and intestine. Some decades later, Feyrter (1938) reported the presence of pale cells 
(helle Zellen) scattered distributed in many organs. It is now well accepted that NE cells 
are found diffusely spread in both the gastrointestinal and respiratory epithelium. In 
addition, these cells are seen in the urogenital tract, skin (Merkel cells) and thyroid 
glands (C cells).  
 
NE cells share some specific functional and morphological properties. They are 
endocrine in the way that they synthesise and release bioactive peptides and amines that 
have effects on other target cells via the blood (endocrine). In addition, their secretory 
products can act directly on neighbouring cells (paracrine) or its own cell (autocrine). 
They are also ascribed neurosecretory properties as they possess several common 
regulatory factors (neurotransmitters) with neurons. Furthermore, some NE cells, like 
pulmonary NE cells, seem to have a rich innervation (Lauweryns et al. 1985). Another 
important property of the NE cells is the uptake of amino acids and transformation of 
these into bioactive amines by decarboxylation, which clarify the previous acronym 
APUD (Amine Precursor Uptake and Decarboxylation) of these cells (Pearse & Polak 
1971). Morphologically, NE cells are identified by their contents of peptides, visualised 
by IHC methods or ultrastructural findings of electron dense granules (dense core 
granules, DCG) using electron microscopy (EM).  
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3.2. The pulmonary NE cell  
 
3.2.1. Terminology and origin  
Since Feyrter reported the presence of some cells without affinity for haematoxylin and 
eosin in the airway epithelium in 1938, the existence of these NE cells in the lungs have 
been a subject of increasing interest (Montuenga et al. 2003). Previously, these cells 
have been named “clear cells”, APUD-cells or Kultschitzky-cells. The present 
terminology, pulmonary NE cells (PNEC), includes cells with NE phenotypes in the 
respiratory epithelium (Van Lommel et al. 1999). These cells are found either as single 
cells among other airway epithelial cells or as aggregates of PNEC, called 
neuroepithelial bodies (NEBs)(Lauweryns & Peuskens 1972). NE cells in respiratory-
like systems are found in most of the species investigated, such as amphibians, reptiles, 
birds, mammals and even in gill filaments of fish (for review, see Van Lommel et al. 
1999).  
 
The embryological origin of the PNEC has been a subject of debates. In the past, 
suggestion of a neuroectoderm (neural crest) origin of PNEC has been made based on 
the similarities in chemical, functional and morphological qualities with neural derived 
cells. This hypothesis has been supported by findings of expression of neural cell 
adhesion molecule (NCAM) in NEBs, which is a membrane-bound protein expressed 
by cells of neuroectoderm origin (Ito et al. 1995). Another argument for this hypothesis 
is the necessity of a critical transcription factor (achaete-scute homologue-1) for 
neuronal development in the formation of mouse PNEC (Borges et al. 1997). However, 
evidence for an endodermal origin has also been found. Ito et al. reported formation of 
NEBs in cultures of foetal airway epithelium without neural tissue or mesenchyme, 
indicating that they were derived from airway epithelium (1997). Futhermore, the 
airway epithelium, like the upper gastrointestinal tract with its NE cells, are developed 
from the primitive foregut. However, this topic has not been fully clarified.  
 
3.2.2. Localisation and morphology  
In humans, single PNEC are found scattered in the respiratory epithelium from the nose 
to the bronchioalveolar region, while NEBs are usually found in the intrapulmonary 
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airways. PNEC are often triangular in shape, with the main cytoplasmic contents 
located near the basal membrane. The apical portion is narrowed and may reach the 
airway lumen. NEBs are often located at airways bifurcations or bronchioalveolar 
junctions, occupying strategic positions for sensing of air contents. They consist of 
clusters of PNEC forming an intraepithelial “organ”, which is innervated at its basal 
part and with protruding microvilli into the airway lumen at its apical part (Montuenga 
et al. 2003) (Figure 1). Most of the luminal surface are covered with adjacent cells like 
Clara cells or type 1 or 2 pneumocytes (Ito 1999).  
 
3.2.3. Markers and quantification 
The ability to produce and store peptides and amines are utilized to identify 
PNEC/NEBs in the lung (Figure 1). Using IHC methods with antibodies against peptide 
products like calcitonin gene-related peptide (CGRP), gastrin releasing peptide (GRP, 
mammalian bombesin) and calcitonin separates PNEC easily from other epithelial cells 
(Scheuermann 1997). In addition, general NE markers as neuron-specific enolase 
(NSE), chromogranin A (CgA), synaptophysin (SYN) and neural cell adhesion molecule 
(NCAM) are also used for visualisation of NE cells in the lung, as well as the main 
amine in the vesicles - serotonin (5-hydroxytryptamine, 5-HT) (Lauweryns et al. 1987; 
Gosney et al. 1988). Even though some similarities exist, important differences in the 
specificity of the markers are observed between different species. 
 
Owing to the rarity and scattered distribution of the PNEC and NEBs in the lung, the 
quantification of NE cells in the respiratory system has been a challenge. Different 
methods of quantification, like counting all NE cells in serial paraffin sections or in a 
whole-mount preparation (Peake et al. 2000) have revealed different results that are 
difficult to compare. However, in most studies and species the number of PNEC is 
found at its maximum around the time of birth, and thereafter declining (Redick & 
Hung 1984). It seems that NEBs are most frequent in animals with immature lungs at 
birth, such as rodents. In adult humans, the reported number of NE cells among airway 
epithelial cells has been varying from 1 – 12.5 PNEC / cm basement membrane, or up 
to 0.5 % of all the epithelial cells (Boers et al. 1996). In a recent study by 
Weichselbaum et al, the area densities of PNEC in normal human respiratory epithelium 
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were reported ranging from 65/mm2 to 250/mm2, using confocal microscopy of whole-
mounts preparations (2005). 
 
 
Mash1+
Microvilli
NE products NE markers
NCAM
NSE
PGP 9.5
Synaptophysin
NADPH 
oxidase
Bombesin, GRP
Somatostatin
CGRP
Calcitonin
Substans P
Serotonin
Chromogranin A
DCV
Airway lumen
 
 
 
Figure 1. Diagram of pulmonary neuroendocrine (NE) cells (PNEC) forming a neuroepithelial 
body (NEB) with some of their secretory products, membrane proteins and general NE markers. 
GRP: gastrin releasing peptide; CGRP: calcitonin gene-related peptide; NSE: neuron-specific 
enolase; PGP 9.5: protein gene product 9.5; NCAM: neural cell adhesion molecule; DCV: dense 
core vesicles; Mash1+: positive mammalian achaete-scute 1 complex (neuronal transcriptional 
factor). 
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3.3. Functions of the pulmonary NE system 
 
3.3.1. Airway oxygen sensors 
NEBs are thought to be specialized airway oxygen (O2) sensors (Figure 2). They are in 
close contact with nerve fibres, and were previously thought to be mainly afferently 
innervated from the vagus nerve. However, recent studies have shown that the 
innervation may be more complex, including spinal sensory and intrinsic bronchial 
nerve fibres connecting individual NEBs and PNECs (Adriaensen et al. 2003; Pan et al. 
2004). Products secreted from NEBs may therefore act as neurotransmitters, which 
induce both stimuli to the central nervous system and accommodation of local 
regulatory axon reflexes.  
 
Airway hypoxia is a powerful stimulus to NEBs and leads to exocytosis of DCV 
containing peptides and serotonin (Cutz et al. 1993) (Figure 2). In a study by Youngson 
et al., voltage-activated potassium, sodium and calcium membrane currents in rabbit 
NEB culture exposed to hypoxia were detected using the patch clamp technique (1993). 
Hypoxia led to reduced outward potassium current and a subsequent membrane 
depolarisation. The precise mechanism of O2 sensing is not fully known, but a 
membrane-bound O2-sensing enzyme complex, such as NADPH oxidase, is thought to 
be the potential receptor (Fu et al. 2000). In the postulated model for oxygen sensing, 
hypoxia affects NADPH oxidase via reduced O2 concentration, which leads to reduced 
production of reactive O2 derivates. This further induces closure of voltage-gated 
potassium channels, which in turn leads to membrane depolarisation and opening of 
calcium channels. The influx of calcium finally triggers release of stored substances 
from secretory vesicles (for review see Cutz & Jackson 1999).  
 
The impact of the ability of pulmonary NE cells to sense the alveolar contents of O2 and 
react upon hypoxia is not fully known in adults, but in the neonatal lung this system 
seems essential (Bolle et al. 2000). At birth the O2-sensing cells of the carotid body, 
which are activated by blood hypoxemia, have a low chemo-sensitivity, and may react 
incomplete in the rapid homeostatic responses needed. NEBs, which are abundant at the 
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time of birth, may therefore be important in sensing hypoxia and maintaining 
respiratory control at that time.  
 
Airway lumen
Hypoxia
Tobacco smoke
Irritants
Tissue damage
Capillary vesselNerve fibre
1
1
2
3
4
 
Figure 2. Schematic presentation of a neuroepithelial body (NEB) with some of its functions. 
NEBs are thought as “receptors” sensing different gases or substances in the airways. As a 
response, NE products are released and may act in a 1) paracrine, 2) autocrine, 3) neurocrine or 
an 4) endocrine way. 
 
 
3.3.2. Regulation of lung development 
The high number of pulmonary NE cells in the late foetal and neonatal period is thought 
to be related to the development of the lung. During pulmonary organogenesis, PNEC 
are the first cell type to become mature. They are differentiated in a centrifugal pattern, 
from the central airways and subsequently into the peripheral airways (Sorokin et al. 
1993). It is postulated that the peptides secreted from PNECs have a paracrine 
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stimulatory effect on surrounding epithelial cells responsible for lung maturation (Hoyt 
et al. 1993). BLPs and CGRP seem to have mitogenic and maturing effects. They serve 
as growth factors for several pulmonary cell types and stimulate airway branching and 
differentiation of cells (Emanuel et al. 1999).  
 
In addition, it is known that mechanical stretch is important for lung growth and 
differentiation in the foetal period. In a recent study by Pan et al., PNEC/NEBs are 
proposed to have mechanoreceptor properties in addition to chemoreceptor qualities 
(2006). They found that mechanical strain was an important stimulus for release of 
serotonin from foetal PNEC via mechanosensitive channels. The release of serotonin 
was independent of potassium-mediated exocytosis, which is the predominant way of 
hypoxia-induced secretion of serotonin. Taken together, this illustrates the important 
role of the pulmonary NE system in lung development.   
 
3.3.3. Regulation of pulmonary blood flow 
It has been known for decades that alveolar hypoxia induces pulmonary 
vasoconstriction (hypoxic pulmonary vasoconstriction, HPV) (von Euler 1946). This 
physiological response is important for optimal oxygenation of the blood. In 
insufficiently ventilated parts of the lung, the vasoconstriction results in re-distribution 
of blood to better ventilated regions. The basic mechanisms of the HPV are not 
completely understood, but the complex reaction seems to involve multiple mediators 
from different cell types, including PNEC/NEBs (Dumas et al. 1999). Several products 
of pulmonary NE cells have vasoactive properties. Serotonin, which is secreted from the 
PNECs exposed to hypoxia, is a strong pulmonary vasoconstrictor (Fu et al. 2002). 
Furthermore, CGRP, which is a pulmonary vasodilator, is tonically secreted in 
normoxic conditions. During hypoxia, the release of CGRP is reduced and may result in 
a vasoconstriction (Helset et al. 1995). 
 
3.3.4. Regulation of bronchial tonus 
Several studies support the view that NE cells of the lung could have a regulatory role 
of the bronchomotor tonus of the airways. The neuropeptide CGRP is found to constrict 
airway smooth muscle cells in cultures (Palmer et al. 1987).  Furthermore, hypoxia is 
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associated with reduced CGRP release from the pulmonary NE cells (Roncalli et al. 
1993; Helset et al. 1995) and may result in a physiological bronchodilatation. In 
addition, studies on guinea pig tracheal preparations have shown that the spontaneous 
tonus in these preparations is partly controlled by NE cells of the airways (Skogvall et 
al. 1999). 
 
3.3.5. Immunomodulatory effects 
Some studies have suggested a role of PNECs/NEBs in the immunological responses of 
the airways. Secreted peptides may modulate the inflammatory reaction in diseases like 
asthma and chronic obstructive lung disease (COPD). Sensitisation with ovalbumine 
stimulates PNECs to produce and store secretory substances that are released when 
exposed to antigens (Bousbaa et al. 1994; Tsukiji et al. 2004). The secretory products 
may have both pro- and anti-inflammatory effects. One example is CGRP, that has 
chemotactic effects on eosinophils in the airways (Bellibas 1996), and in addition 
inhibit edema-promoting actions of inflammatory mediators (Raud et al. 1991).  
 
 
3.4. PNEC and non-malignant respiratory diseases 
Morphological changes of the pulmonary NE system are found in many non-malignant 
conditions (Table 1). The hyperplastic alterations include both increased number of 
single PNECs/NEBs and the cell density of each NEB. Most often these changes are 
seen in lung diseases involving inflammatory or fibrotic processes. In conditions like 
asthma (Stanislawski et al. 1981), chronic bronchitis and emphysema (Gosney et al. 
1989), bronchiectasis (Gould et al. 1983; Pilmane et al. 1995), cystic fibrosis (Dovey et 
al. 1989) and eosinophilic granuloma (Aguayo et al. 1990) the number of 
immunoreactive NE cells is increased compared to normal lungs.  
 
The important question whether the hyperplasia of PNEC/NEBs is a primary or 
secondary occurrence has so far not been clarified (Aguayo 1994b). Many of these 
diseases are chronic diseases characterised by persistent inflammation leading to 
structural changes and destruction of normal lung tissue. By time this eventually leads 
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to chronic hypoxia, and it is postulated that hypoxia may be the major stimulating factor 
for NE cell proliferation. In addition, many of the chronic lung diseases are caused by 
long-term cigarette smoking which also may lead to hyperplasia of NE cells. 
 
Furthermore, in many pulmonary diseases with a damaged lung parenchyma, NEBs 
may play an important role as growth regulators. They secrete peptides that are thought 
to be involved in the repairing process, and may stimulate differentiation of primitive 
epithelial cells. 
 
Other non-inflammatory conditions like pulmonary hypertension are associated with 
PNEC hyperplasia (Heath et al. 1990). This could in fact be a consequence of chronic 
alveolar hypoxia. However, it has also been proposed that NE peptides or amines such 
as serotonin may have bioactive effects on the pulmonary vasculature, representing a 
primary cause for vascular remodelling (Marcos et al. 2004). 
 
Table 1  Pulmonary conditions and exposures associated with 
 hyperplasia of pulmonary NE cells 
Human conditions Experimental animal models 
Asthma  Acute and chronic hypoxia 
Chronic bronchitis, emphysema Hyperoxia 
Eosinophilic granuloma Tobacco smoke 
Bronchiectasis Nitrosamines 
Cystic fibrosis Naphthalene 
Tobacco smoking Ozone 
Pulmonary hypertension Asbestos 
Bronchopulmonary dysplasia Silica 
Sudden infant death syndrome Diaphragmatic hernia 
Congenital diaphragmatic hernia  
Diffuse idiopathic NE cell hyperplasia  
Tumours  
Sources: (Van Lommel et al. 1999; Van Lommel 2001; Linnoila 2006) 
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The fact that PNEC seem to be important for lung development, has initiated several 
studies looking for changes in the pulmonary NE system in paediatric lung disorders.  In 
bronchopulmonary dysplasia, a condition secondary to mechanical ventilation and high 
O2 levels in infants, high number of PNEC/NEBs is reported in addition to other tissue 
damages (Johnson et al. 1982). Other paediatric conditions associated with hyperplasia 
of pulmonary NE cells compared to age-matched controls are sudden infant death 
syndrome (Cutz et al. 1997), congenital pneumonias (Saad et al. 2003) and congenital 
diaphragmatic hernia (Asabe et al. 1999). The reasons for these alterations are not fully 
known, but may be related to hypoxia, tissue injury and inflammation.  
 
 
3.5. Lung cancer 
Lung cancer is currently one of the most common neoplasms worldwide and is the most 
frequent cause of cancer death in men. The most important etiological agent of lung 
cancer is tobacco smoke, accounting for approximately 85-90% of all cases. Other 
etiological factors include exposure to asbestos, nickel, chromium, polycyclic aromatic 
hydrocarbons, radon and presents of pulmonary fibrosis or genetic susceptibility (Albert 
2004).  
 
3.5.1. Preinvasive lesions 
Carcinogenesis of lung cancer is thought as a multistep process involving 
transformation of normal bronchial epithelium through a continuous spectrum of 
preneoplastic lesions into invasive carcinoma (for review see Kerr 2001). Along with 
the morphological changes, increasing molecular and genetic abnormalities occur. This 
is best recognised for squamous dysplasia and subsequent carcinoma in situ, which is 
observed prior to development of invasive squamous cell carcinoma. Two other 
preinvasive lesions have recently been classified by WHO (Travis et al. 1999). Atypical 
adenomatous hyperplasia may be a precursor for adenocarcinoma and diffuse idiopathic 
neuroendocrine cell hyperplasia (DIPNECH) is considered as a precursor for tumorlets 
and carcinoids (see section 3.5.7). However, lung cancer is often histological 
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heterogenic and transition and dedifferentiation of the tumour may complicate the 
finding of a single cell type as the cell of origin. 
 
3.5.2. Classification 
The histological diagnosis of lung cancer is based primarily on light microscopy, 
supported by IHC and EM. Microscopic findings are classified according to the 
accepted WHO/IASLC (World Health Organisation/International Association for the 
Study of Lung Cancer) Histological Classification of Lung and Pleural Tumours (Travis 
et al. 1999). The four most common histological types of lung cancer are squamous cell 
carcinoma, adenocarcinoma, small cell carcinoma (SCLC) and large cell carcinoma 
(for review see Travis 2002). However, many of the lung tumours display a heterogenic 
picture with a mixture of histological types. In such cases, the portion that is most 
highly differentiated defines the specific diagnosis, except for tumours that contain 
features of SCLC, which are classified as SCLC. However, the currently most clinical 
relevant classification is the distinction between SCLC and the other sub-types, 
collectively named non-small cell lung carcinoma (NSCLC). These two types of 
tumours have major differences in presentation, progression and response to therapy.  
 
3.5.3. Squamous cell carcinoma 
Squamous cell carcinoma accounts for approximately 30 % of all lung carcinomas 
(Travis et al. 1995). The overall incidence of this histological type is decreasing in 
North America and Europe, but in some countries like Norway it is raising rapidly 
among women (Devesa et al. 2005).  Most of these are central tumours, originates in a 
segmental or lobar bronchus and often grow intraluminally. Large tumours often present 
with a central necrosis which leads to cavitation. Histopathological features include 
intracellular bridging, squamous pearl formation and individual cell keratinisation.  
 
3.5.4. Adenocarcinoma 
Approximately 30-35 % of lung carcinomas are adenocarcinomas, and the trend is 
increasing in both gender the latest decades (Devesa et al. 2005). They often present as 
peripheral tumours. Most adenocarcinomas are histologically heterogeneous, and may 
grow in an acinar/glandular or papillary pattern. Bronchioalveolar carcinoma (BAC) is 
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a subtype of adenocarcinoma characterised by a growth pattern along the alveolar septa 
but without invasive growth (Beasley et al. 2005). 
 
3.5.5. Large cell carcinoma 
Large cell carcinoma accounts for about 9 % of all lung carcinomas (Travis et al. 
1995). The histological diagnosis of large cell carcinoma is applied to tumours that do 
not have the typical pattern of SCLC and show no squamous or glandular differentiation 
by light microscopy (Travis et al. 1999). They often have large cells with abundant 
cytoplasm and large nuclei with prominent nucleoli. Several subgroups of large cell 
carcinoma are recognised by the WHO/IASLC classification, including the clinical 
important large cell neuroendocrine carcinoma (LCNEC) (see section 3.5.9). 
 
3.5.6. Small cell carcinoma 
Approximately 20 % of all lung carcinomas are SCLC. According to a recent published 
multinational study this type of lung cancer is slowly decreasing in most counties both 
in North America and Europe among men (Devesa et al. 2005). In women, however, the 
incidence is increasing especially in Norway and the Netherlands. SCLC is often 
situated as a central perihilar mass, with infiltration of submucosa and peribronchial 
tissue (Albert 2004). The histological appearance is characterised by small round or 
fusiform cells with scanty cytoplasm and finely granular nuclear chromatin with 
absence of nucleoli. In addition, the mitotic rates are high (> 10 mitoses/2 mm2). A 
combination of SCLC with other histological types is seen in up to 28 % of SCLC, and 
is classified as combined SCLC (Nicholson et al. 2002).  
 
3.5.7. Pulmonary NE tumours 
The WHO/IASLC classification incorporates several different lesions into the term NE 
proliferations and neoplasms as summarised in table 2 (Travis et al. 1999). These 
lesions show NE features like NE growth pattern, express positive NE markers and 
possess DCV in the cytoplasm. 
 
Hyperplasia of NE cells, as described in section 3.4, is often seen as secondary lesions 
in conditions with inflammation, hypoxia, and exposure to toxic or irritating substances. 
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When increasing number of PNEC/NEBs is detected in the airway epithelium without 
known causes, the term diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
(DIPNECH) is used (Aguayo et al. 1992b). The findings of small aggregates of NE 
cells named tumourlets (< 5mm in diameter) or carcinoids (> 5mm) in DIPNECH, 
propose this hyperplasia as a potential precursor for carcinoid tumours (Kerr 2001; 
Adams et al. 2006). DIPNECH is previously considered as a rare disease, most often 
seen in non-smoking females without other known lung disease. However, a recent 
retrospective histological study by Davies et al., concludes that DIPNECH occurs more 
commonly than previously thought and may be associated by impaired lung function 
and atypical carcinoids (Davies et al. 2006). Fortunately, the condition is considered as 
an indolent lesion as the majority of the cases remained stable for many years. 
 
Table 2  WHO Classification of Pulmonary Neuroendocrine Lesions 
NE cell hyperplasia and tumourlets  
 NE hyperplasia 
 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
 Tumourlets 
Tumours with NE morphology  
 Typical carcinoid 
 Atypical carcinoid 
 Large cell NE carcinoma 
 Small cell carcinoma 
Non-small cell carcinoma with NE differentiation  
 
3.5.8. Carcinoid tumours 
Carcinoid tumours account for 1-2 % of all invasive lung carcinomas (Travis et al. 
1995). They are often found in younger patients without a smoking history and may be 
associated with paraneoplastic syndromes. The histological pattern consists of cells with 
finely granular cytoplasm and nuclei with a finely granular chromatin. They are 
characterised by an organoid or rosette-like growth pattern. Typical and atypical 
carcinoids are distinguished by the number of mitoses (< 2 mitosis/ mm2 versus 2-10 
mitosis/ mm2) (Travis et al. 1999). 
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3.5.9. Large cell NE carcinoma 
In the latest classification by WHO/ IASLC the term large cell NE carcinoma has 
become a separate entity (Travis et al. 1999). This sub-group of large cell carcinoma is 
recognised by the NE morphology (organoid pattern) and positive NE markers 
confirmed by immunohistochemistry. Mitotic counts are high and necrosis is common. 
Whether this recently classified type of malignancy should be regarded as a separate 
clinical entity, and treated like other highly malignant NE carcinomas such as SCLC, 
has not been clarified yet (Harada et al. 2002; Fernandez & Battafarano 2006). 
 
3.5.10. Non-small cell carcinoma with NE differentiation 
It is known that some NSCLC with no obvious histological signs of NE features 
(organoid/palisade -like growth pattern) show IHC and ultrastructural characteristics of 
NE differentiation (Linnoila et al. 1988; Baldi et al. 2000). These are collectively 
referred to as NSCLC with NE differentiation (NSCLC-ND), but are not formally 
classified as a separate entity as its clinical and prognostic significance has been 
questioned (Carnaghi et al. 2001; Ionescu et al. 2007). The portion of NE differentiated 
tumours has previously been regarded as low (< 20 %) among NSCLC (Baldi et al. 
2000). However, this largely depends on the sensitivity of the methods used for 
detection of NE markers. Fresvig et al. have previously shown that a higher percentage 
of squamous cell carcinoma of the lung has IHC signs of NE differentiation (10 of 29) 
(Fresvig et al. 2001), especially when techniques for increasing the sensitivity of IHC 
staining like the tyramide signal amplification (TSA) method was used. 
 
 
3.6. Chromogranin A 
The human CgA is a single-chain, acidic, water-soluble glycoprotein consisting of 439 
amino acids. In the 1960s, CgA was originally discovered in chromaffin granules of the 
adrenal medulla (Banks & Helle 1965; Blaschko et al. 1967). It is now considered as a 
secretory protein found in DCV of several endocrine and NE cells where it is co-
released with other peptide hormones from the secretory granules (Nobels et al. 1998). 
CgA has been found in the adrenal medulla, in nerves and throughout the diffuse NE 
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system, including the anterior pituitary gland, the thyroid and parathyroid glands, islet 
cells of the pancreas, NE cells of the bronchial tree and GI tract and Merkel cells of the 
skin (Feldman & Eiden 2003). 
 
The function of CgA has mainly been linked to its presence in the secretory granules. 
CgA binds calcium and aggregates in its presence in the acidic granule interior. It is 
therefore proposed that CgA is important for secretory granulogenesis, sorting of 
peptides and granule maturation (Feldman & Eiden 2003). In addition, CgA is 
considered as a prohormone that is intra -or extracellularly degraded in an organ-
specific process, generating several bioactive peptides exerting its effects on other 
organs. Some examples of CgA-derived peptides are; pancreastatin, which is able to 
inhibit insulin secretion in the pancreas; parastatin, which inhibits parathormone 
secretion in the parathyroid gland and vasostatins with vasoactive properties (Taupenot 
et al. 2003). 
 
The serum concentration of CgA is the sum of all CgA secreted from endocrine or NE 
tissue. Elevated levels may therefore reflect hyperplasia of NE cells, an increased 
secretion of NE peptides or a decreased elimination of CgA from the body as seen in 
renal failure. In patients with NE neoplasia elevated levels of circulating CgA are 
detected (Syversen et al. 2004), and there exists a strong correlation between the level 
of CgA and the volume of the NE tumour (Hsiao et al. 1990).  
 
 
3.7. Carbon monoxide 
Carbon monoxide (CO) is a colourless, odourless gas produced by incomplete 
combustion of carbon-containing materials. Its main environmental sources include 
vehicles, industrial processes, and other fuel combustion sources. Indoor sources may 
be gas-, oil-, and wood-burning stoves or heaters (WHO 1999). In addition, CO is a 
product of cigarette smoking, and the greatest source of individual exposure to CO is 
probably tobacco smoke. CO constitutes about 5% of total effluent of the vapour phase 
of mainstream smoke. And the concentration of CO in the smoke inhaled into the lung 
 
 
28
has been estimated to 400 parts per million (ppm). (Goldsmith & Landaw 1968; WHO 
1999).    
 
CO is also endogenously produced in human tissues, through degradation of 
haemoglobin to bile pigments. Heme is degraded to biliverdin by the enzyme heme 
oxygenase (HO), with the release of iron and CO. Like nitric oxide (NO), CO activates 
guanylyl cyclase to produce cyclic guanosine monophosphate (cGMP), which in turn 
can result in smooth muscle relaxation and vasodilatation. Another important property 
of CO, like NO, is that these are molecules small enough to easily pass across the 
plasma membrane, without binding to receptors or transport-proteins. This enables them 
to act directly on the intracellular target molecule. Therefore, CO is regarded as a 
cellular signal molecule in normal physiology, and may act as a neurotransmitter, 
vasodilator, bronchodilator and inhibitor of platelet function (for review see (Sethi 
2005; Kim et al. 2006). In addition, in small concentrations, it may exert a protective 
role in a wide variety of diseases, with its anti-inflammatory and anti-proliferative 
effects (Ryter & Otterbein 2004).  
 
In high concentrations, CO is a poisonous gas, resulting in a severe hypoxic condition 
with cerebral dysfunction and cardio-respiratory failure. The gas is rapidly absorbed in 
the lungs, and bound to the oxygen-binding site of haemoglobin forming 
carboxyhaemoglobin (COHb). CO binds to haemoglobin about 240 times the affinity of 
oxygen, and in addition causes a left shift in the oxyhaemoglobin dissociation curve. 
These effects lead to both reduced oxygen transport and release of oxygen to the tissues 
(WHO 1999). 
 
Although the effects of acute severe exposure of CO are well known, the effects of 
prolonged low level CO exposure are unclear. Some of the effects may be related to the 
formation of COHb and hypoxia, which are shown in some animal studies leading to 
cardiac hypertrophy, increased haemoglobin and haematocrit (Stupfel & Bouley 1970; 
Turner et al. 1979). However, the results are conflicting, and no information exists of 
long-term effects of CO inhalation on the pulmonary morphology and tumourigenesis.  
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4. Aims of the study 
 
The main purpose of this thesis was to evaluate the possible roles and regulatory 
functions of the pulmonary neuroendocrine (NE) system in physiological and 
pathophysiological conditions and in tumourigenesis. In order to meet this purpose 
several distinct aims were defined. 
 
1. (Paper I) To examine the relationship between the serum levels of the general 
NE marker chromogranin A in humans and  
a. smoking habits 
b. lung function  
c. respiratory symptoms. 
 
2. (Paper II) To examine the long-term effects of inhaled carbon monoxide in rats 
at doses corresponding to tobacco smoking on the  
a. respiratory system 
b. cardiovascular system 
c. tumourigenic processes 
d. the pulmonary NE cells. 
 
3. (Paper III) To examine the expression of different NE markers in surgically 
treated non-small cell lung cancer using  
a. biochemical analyses of patient sera and plasma 
b. immunohistochemical methods with signal amplification techniques 
c. immunoelectron microscopy methods. 
 
4. (Paper IV) To examine the effects of acute intermittent alveolar hypoxia in an 
isolated buffer-perfused and ventilated rat lung model 
a. on the release of NE products in the pulmonary circulation 
b. using immunohistochemical methods for detecting changes in the 
immunoreactivity of the pulmonary NE cells 
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5. Methodological considerations 
 
In the present thesis several different methods and procedures are used which are 
described in details in each paper. Some general methodological considerations are 
given below. 
   
5.1. Study populations 
5.1.1. Human studies 
In paper I all subjects were selected from a sub-study of the Nord-Trøndelag Health 
Study (the HUNT study II). The HUNT study is a cross-sectional survey conducted in 
1995-1997 in the Norwegian county of Nord-Trøndelag representing 71% of the adults 
(> 20 years). The sub-study BONT (the Bronchial Obstruction in Nord-Trøndelag) 
included a 5 % random sample (n = 2 791) of the total study population of the HUNT 
study (n = 65 225) and those reporting asthma or asthma-related symptoms (n = 8 150) 
(Langhammer et al. 2001). From the BONT study 3 groups were randomly selected for 
further serological analysis: 1) never-smokers with normal lung function (n = 1 649), 2) 
ever-smokers with normal lung function (n = 879), and 3) ever-smokers with 
obstructive spirometric values (n = 359). Among these groups random samples of 
Helicobacter Pylori (HP) negative subjects (151, 138 and 116) were further analysed for 
CgA (for details see figure 1 in paper I). The selection of HP negative subjects was done 
to reduce a possible gastric source of CgA as a previous study has shown a relationship 
between infection with HP and hyperplasia of NE cells in the gastric mucosa with 
increased levels of circulating CgA (Sanduleanu et al. 2001).  
The study subjects (n = 20) in paper III were all recruited from the Department of 
Pulmonary Medicine, St. Olavs Hospital, Trondheim. They had a histological confirmed 
NSCLC, Stage I-IIIA (Mountain 1997), and were all treated with a surgically resection 
of the tumour. In addition, one subject with a typical carcinoid was included as a 
positive control. Written informed consent was given prior to the surgery. Both studies 
were approved by the Regional Committee for Ethics in Medical Research and the 
Norwegian Data Inspectorate. 
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5.1.2. Animal studies 
All animal studies (papers II and IV) were performed with Wistar rats. In paper II, 
female rats were used as they are previously well characterised in a long-term exposure 
study in our laboratory (Waldum et al. 1996). In paper IV, male Wistar rats were used. 
This strain and sex has been described in previously published studies of isolated rat 
lung models (Hauge 1968; Helset et al. 1995). The studies were approved by the 
Animal Welfare Committee of the St. Olavs Hospital, Trondheim, the Norwegian 
Council for Animal Research, Oslo, and conformed to the “European Convention for 
the Protection of Vertebrate Animals Used for Experimental and other Scientific 
Purposes” 
 
5.2. Anaesthesia of animals 
In papers II and IV, all animals were anaesthetised with a subcutaneously injected 
mixture of fentanyl 12.5 µg/ml, midazolam 1.25 mg/ml and haloperiodol 0.83 mg/ml at 
doses of 0.4 ml/100g rat weight. This mixture is a local preparation at the Dept. of 
Laboratory Animals, St. Olavs Hospital and gives a deep sedation with a good analgesia 
without respiratory depression. In addition, peripheral perfusion is preserved allowing 
peripheral venous blood sampling. 
 
5.3. Light microscopy 
All tissue specimens for histological and immunohistochemical examination were fixed 
in 4% phosphate-buffered formaldehyde (PBF) for 24 hours, dehydrated in 80 % 
alcohol before embedded in paraffin. Haematoxylin and eosin (H&E) staining was used 
for routine histological evaluation, as described in details in papers II, III and IV. In 
paper II, a commercial Elastica von Gieson staining kit (Merck KGaA, Darmstadt, 
Germany) were used to evaluate the number of muscularized pulmonary arteries as 
described by Keegan et al. (Keegan et al. 2001) and in details in paper II. 
 
5.3.1. Immunohistochemistry 
In papers II, III and IV, IHC methods are used to visualise different cellular proteins. 
Immunohistochemistry is a method used to detect molecules in the cells or tissues. 
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Using specific antibodies in combination with different detection reagents, the antigen-
antibody reaction can be visualised by its in situ localisation in a tissue slide. 
Commonly used detection reagents include fluorescent dyes (for fluorescent 
microscopy), enzymes (for light microscopy) and colloidal gold spheres (for EM).  
The primary antibodies used in the present thesis are both polyclonal and monoclonal. 
Polyclonal antisera contain several different antibodies directed towards different 
epitopes on the antigen. The immunoreaction of the polyclonal antibodies is therefore 
more sensitive than monoclonal antibodies, but has an increased risk of non-specific 
immunoreaction (background staining). On the other hand, monoclonal antibodies are 
more specific but have a lower sensitivity. Therefore, in the present study, monoclonal 
antibodies were used when possible. 
All immunohistochemistry in the present study was done using the two-step EnVision-
system (DakoCytomation, Glostrup, Denmark). EnVision is a staining technique in 
which the primary antibody is followed by a detection reagent that consists of a dextran 
backbone with a large number of peroxidase molecules and secondary antibodies 
coupled. The EnVision-system has been reported to be a very sensitive method that 
allows high dilutions of the primary antibodies without loss of specificity and with low 
non-specific background staining (Sabattini et al. 1998).  
 
5.3.2. Tyramide signal amplification technique 
To further increase the sensitivity of immunohistochemistry, TSA technique was used 
in paper III. This method was first described by Adams (1992) and makes it possible to 
increase the sensitivity up to 1000-fold for several antibodies. By adding biotinylated 
tyramine (tyramide) additional binding sites for peroxidase are created, before the 
reaction is visualised by attaching signal molecules (chromogens) to streptavidin.  
 
5.3.3. NE markers 
Several antibodies towards different NE cell contents are used to visualise NE features 
and cells. The expression of different markers depends on the species examined. In our 
animal studies (papers II and IV) a polyclonal antibody towards CGRP was preferred to 
visualise PNEC and NEBs. CGRP is a secretory protein in NE cells and neurons, and is 
highly expressed in rats (Avadhanam et al. 1997). In the human study (paper III), 
 
 
33
antibodies against CgA, SYN, NSE and NCAM were used. These are among the most 
common NE markers used in human pulmonary immunohistochemistry. NSE is 
considered as a sensitive NE marker, but with a low specificity (Carlei & Polak 1984; 
Brambilla et al. 1992). CgA, which is one of the major matrix components of the NE 
granules, is regarded as a specific NE marker and is easily detected in all human NE 
cells (Nobels et al. 1998). Furthermore, NCAM, a membrane attached molecule, is 
expressed in most NE cells and NE tumours (Jin et al. 1991; Lantuejoul et al. 1998).    
 
 
5.4. Electron microscopy 
In papers II and III, EM was used for ultrastructural analyses. All tissue samples were 
cut into 1mm3 blocks, immediately immersed in 2.5% glutaraldehyde and post-fixed in 
2% osmium tetroxide for 60 min, before the samples were dehydrated in a graded series 
of ethanol and propylene oxide and embedded in epoxy resin LX 112 (Ladd Research 
Industries, Willinton, VT, USA). The samples were further sliced in ultra-thin sections 
(70-90nm, RMC MTX Ultramicrotom, Boecklerand, Germany) and mounted on grids 
before being contrasted with uranyl acetate and lead citrate. For conventional 
transmission EM copper grids were used (paper II). Nickel grids were used for IEM to 
prevent chemical precipitations. The grids were further examined in a JEOL 1011 
transmission EM (Tokyo, Japan). 
 
5.4.1. Immunoelectron microscopy 
Like immunohistochemistry, the reason for using IEM is to localise molecules in the 
cells, but at an ultrastructural level. Immunolabelling is performed either before (pre-
embedding) or after (post-embedding) the embedding of the tissue. The latter was done 
in the present study (described in details in paper III). Some of the advantages of the 
post-embedding technique are that the ultrastructure is well preserved, the method is 
relatively easy to perform, and it is a reliable technique for localising intracytoplasmic 
antigens (Merighi et al. 1992). Using primary antibodies towards sub-cellular structures 
or molecules, which are further attached to secondary antibodies conjugated with an 
electron dense particle, specific structures are easily detected and distinguished from 
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normal cellular contents. The most common detection reagent used in IEM is colloidal 
gold spheres (5-50nm in diameter). Labelling efficiency of the gold probe seems to be 
inversely proportional to the diameter of the gold particle, and for single procedures 
10nm gold probes are therefore recommended, as used in paper III (Merighi et al. 
1992).  
 
Before labelling with the primary antibody, retrieval of antigens of the epoxy embedded 
specimens must be performed. In paper III, antigen retrieval was achieved by placing 
the grids in an alkaline solution, (ph 10, Target Retrieval Solution, TRS, Dako 
Corporation, Carpinteria, CA, USA) and heating in an autoclave at 140°C for 15 min. In 
a study by Fossmark et al. at our laboratory, the CgA labelling efficacy after antigen 
retrieval in an alkaline solution was higher in an autoclave at 135°C compared to a 
microwave at 100°C for NE vesicles without deterioration of the ultrastructure (2005a).   
 
 
5.5. CO exposure 
 
5.5.1. Exposure chambers 
For experimental inhalation studies, well designed exposure chambers are essential. The 
chambers with its equipments should be able to give a constant concentration of the gas 
in the chamber, allow observation of the animals and measurement of the exposed 
environment, and, for safety reasons, leakage of the gas to the ambient air should be 
avoided. In addition, sufficient area and easy access to the animals should be provided, 
to facilitate the cleaning and feeding. To meet these requirements, three stainless steel 
and glass chambers were used for gas exposure in the CO inhalation study (figure 4). 
The chambers, each 650 l, were designed as a cube with a conical top and bottom, as 
described in a previous exposure study from our laboratory (Waldum et al. 1996). A 
mixture of hospital medical quality air and CO (AGA, Oslo, Norway) was continuously 
circulated through two of the chambers and created a constant CO concentration of 200 
ppm. Pure hospital medical quality air was circulated through the control chamber, at 
equal rate to the two CO exposed chambers. The CO concentration, chamber 
temperature and humidity were monitored daily.  
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Figure 4. Stainless steel and glass chambers used for the chronic CO inhalation study (paper II). 
A mixture of CO and air was continuously circulated through the exposure chambers (from the 
left, 1st and 2nd chamber) creating a CO concentration of 200 ppm. Only pure air was circulated 
through the chamber containing the control animals (3rd chamber). 
 
 
5.5.2. CO exposure protocol 
The animals in the CO inhalation group were exposed to CO for 20 hours a day, five 
days a week (Monday to Friday) for 72 weeks. During the weekends they were only 
exposed to pure air for practical reasons. The animals had only access to food when not 
exposed to CO, to avoid any gas contamination of the food, and fulfil the criteria of a 
pure inhalation study. All animals were taken directly from the exposure chambers 
before sacrificing or blood sampling. 
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5.6. Isolated perfused and ventilated rat lung 
Isolated animal organ models are well suited for exposure studies on endocrine or NE 
systems. In our laboratory, we have previously developed and used an isolated 
vascularly perfused rat stomach model for studies on the endocrine function of the 
stomach (Kleveland et al. 1986; Sandvik et al. 1989). Given the knowledge that the 
respiratory organs also show endocrine or NE properties, the purpose of paper IV was to 
investigate the effects of intermittent hypoxia (IH) on the release of NE products from 
the rat lung. To exclude any systemic origin of the bioactive substances, the 
experiments were performed on isolated buffer-perfused and ventilated rat lungs. This 
model allows full control over the humoral factors released in the pulmonary circulation 
since the vascular perfusate is not recirculated. In addition, the isolated lung model is a 
viable organ with intact metabolic function for several hours (Baker et al. 1999). The 
present isolated perfused and ventilated rat lung model is developed in our laboratory 
but methodologically based on previously described isolated rat lungs by Hauge and 
Bjertnæs (1968; 1977). The model is described in detail in paper IV, and only some 
general considerations are discussed below.   
 
5.6.1. Isolated lung preparation 
After the rats were deeply anaesthetised, a tracheostoma was made and the animals were 
connected to a rodent ventilator. Thereafter, the lungs were exposed via a medial 
sternotomy. To prevent thrombi formation in the lungs, 350 IU Heparin (LEO, 
Copenhagen, Denmark) was injected into the right ventricle before the lungs were 
removed from the thorax.  The ventilation was then stopped and the trachea-lung-heart 
preparation was dissected free from the chest. During this procedure special care was 
taken not to touch the fragile lungs. Only morphologically undamaged lungs without 
leakage were used. The inflow cannula with two additional outlets (one for pressure 
monitoring and the other serving as an air trap) was then placed into the pulmonary 
artery and ligated. Through a cut in the left ventricle, the outflow cannula (with one 
additional outlet for pressure monitoring) was placed in the left atrium and secured with 
a band around the ventricles. The preparation was mounted in a special designed 
humidified water-jacketed perspex chamber (36-37 ºC) suspended by the air-tap tube of 
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the pulmonary artery cannula, and connected to the ventilator and the tubes for in- and 
outflow and pressure monitoring. This allowed the lungs to expand freely during the 
ventilation.  
 
5.6.2. Perfusion, ventilation and measurement 
The lungs were perfused through the pulmonary artery with a pre-heated (38 ºC) Krebs-
Ringer-albumin buffer (paper IV) in single-pass perfusion using a peristaltic perfusion 
pump (Ismatec IPC, Glattbrugg, Switzerland). Bovine serum albumin (Sigma-Aldrich, 
St. Louis, MO, USA) was used as a buffer-colloid to prevent pulmonary oedema. A 
positive pressure ventilator (Harvard Rodent Ventilator Model 683, Massachusetts, US) 
was used for ventilation with either a normoxic gas-mixture (21% O2, 5% CO2, 74% N2, 
AGA, Norway) or a hypoxic gas-mixture (2% O2, 5% CO2, 93% N2, AGA, Norway) 
with a tidal volume of 2 ml, a respiratory frequency of 80/min and an end-expiratory 
pressure of 2 cm H20 to avoid collapse of the lungs. The pressure in the pulmonary 
artery (Ppa) and left atrium (pulmonary venous pressure, venous outlet pressure, Ppv) 
were continuously recorded by pressure transducers (Marquette Tramscope, Marquette 
electronics inc, Milwaukee, WI, USA) that were connected to tubes from the inlet and 
outlet cannulas. The Ppv was adjusted and kept constant at minus 1 mmHg during the 
experiment. Since the perfusion flow and the Ppv were kept constant, changes in the 
pulmonary vascular tonus were reflected as changes in Ppa. 
 
5.6.3. Experimental protocol 
After 15 min equilibration on normoxic gas, the hypoxic exposed lungs were alternately 
ventilated with the hypoxic and normoxic gas-mixture for cycles of 5 min duration. The 
control lungs were ventilated with normoxic gas only. During the experiment samples 
of the outflow perfusate were repeatedly collected.  
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5.7. Measurements and analyses 
 
5.7.1. Animal and organ weights  
In paper II, the animal weights were measured every 4th week. During the exposure 
period, all rats from the same cage were weighed together, and the weights were 
reported as means. At the end of the study, each animal and the reported organ were 
weighed separately.  
 
5.7.2. Spirometry  
In paper I, spirometric measurements from the BONT study were used for classifying 
subjects according to lung function. Flow/volume spirometry was recorded by HUNT 
staff using pneumotachographs according to the recommendations of the American 
Thoracic Society (ATS 1995), as described in detail by Langhammer et al. (2001). The 
predicted forced expiratory volume in one second (FEV1%) was calculated using 
prediction equations estimated for the population of Nord-Trøndelag (Langhammer et 
al. 2001).  
 
5.7.3. Immunoassays for Helicobacter Pylori and NSE 
In paper I, a commercial enzyme immunoassay (Pyloriset EIA-IgG, Orion Diagnostica, 
Espoo, Finland) was used for detection of immunoglobulin G antibodies to Helicobacter 
Pylori in serum. The analyses were done at Levanger Hospital, The Nord-Trøndelag 
Hospital Trust, and titer values >300 were scored as positive.   
 
In paper III, an electrochemiluminescence immunoassay (ECLIA) method with reagents 
from Roche Diagnostics GmbH (Mannheim, Germany) was used for measurement of 
serum NSE. These tests were performed at the Department of Biochemical Medicine, 
St. Olavs Hospital, Trondheim. 
 
5.7.4. Radioimmunoassays 
Circulating CgA in papers I and III were analysed at the Department of Biochemical 
Medicine, St. Olavs Hospital, Trondheim, using a commercial radioimmunoassay (RIA) 
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method with reagents from EuroDiagnostica, Malmø, Sweden. This method is based on 
polyclonal antibodies raised in rabbits against a purified fragment containing amino acid 
sequence 116-439 of the CgA molecule, and has been shown to detect both intact CgA 
and fragments of CgA (Stridsberg et al. 1993; Stridsberg et al. 1995).  
 
In paper IV, perfusate levels of BLPs and serotonin were analysed at the Department of 
Cancer Research and Molecular Medicine (Laboratory of Basal Physiology) by 
competition binding assays using commercially available RIA kits. BLPs 
immunoreactivity was measured using a Bombesin RIA kit (Phoenix Pharmaceuticals, 
Belmont, CA, USA), where the antibody has a 100% cross-reactivity with bombesin, 
50% with porcine gastrin releasing peptide (GRP) and < 0.01% with substance P and 
vasoactive intestinal peptide (VIP). The lower limit of detection was 5.8 pg/tube. Levels 
of serotonin were determined using a Serotonin-RIA kit (DLD Diagnostica GmbH, 
Hamburg, Germany) with a 100% antibody cross-reactivity for N-Acetylserotonin, and 
a lower limit of detection of 2 ng/ml in liquor. The samples were assayed in duplicate 
and calculated mean values were used. 
 
5.7.5. Quantification of NE cells  
In the animal studies (papers II and IV), quantification of pulmonary NE cells was done 
using antibodies to the secretory peptide CGRP, which is highly expressed in PNECs 
and NEBs in rat (McBride et al. 1990). In addition, antibodies to CgA were used in 
paper IV. Both PNECs and NEBs were identified as distinct positive immunoreactive 
cells with a stained cytoplasm located within all levels of the respiratory tree down to 
the respiratory bronchioles. The size of the NEBs was reported as number of 
immunoreactive cells with a visible nucleus. In addition, single PNEC in the airways 
were counted. Total number of NE cells/NEBs was divided by the total area of the 
section, which was calculated from photos of the lung sections using iTEM Analysis 
(Soft imaging system GmbH, Münster, Germany) software.  
 
5.7.6. Statistical analyses 
All data were analysed using the statistical package for social sciences (SPSS, version 
13.0, Chicago, IL, USA) and GraphPad Prism Software (version 4.01, San Diego, CA 
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USA). The data are presented as means ± standard deviation (SD) or standard error of 
the mean (SEM). The non-normal distributed data for serum CgA (papers I and III) and 
NSE (paper III) are presented as medians with interquartile range. A two-tailed p-value 
< 0.05 was considered statistically significant. 
 
For continuous normally distributed data Student`s t-test and analyses of variance 
(ANOVA) with Bonferroni`s post hoc test were used for comparisons between two or 
multiple groups, respectively. The non-parametric Mann-Whitney U test was used for 
comparisons between two groups of non-normally distributed data. In paper I, the 
variable serum CgA was transformed to log-CgA to achieve a normal distribution of 
data, before analyses were performed stratified by sex. Differences between proportions 
were analysed using the Chi-squared test and Fisher`s exact test. The Spearman rank 
correlation test was used to test the correlation between non-normally distributed 
variables such as serum CgA and plasma NSE in paper III.  
 
A multiple linear regression model was used in paper I to assess the impact of the 
independent variables age, pack-years, FEV1%, presence of respiratory symptoms and 
serum creatinine on the dependent variable log-CgA. Analyses were done separately for 
each sex. The assumptions for linear regression analyses, such as normally distributed 
residuals, constant variability of the independent variables and a linear relation between 
the independent and dependent variable, were met for this model.  
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6. Results and discussion 
 
6.1. The pulmonary NE system and respiratory pathophysiology 
 
6.1.1. Serum levels of CgA in smoking-induced airway diseases 
Based on morphological studies, it has been proposed that the NE system may play an 
important role in the pathogenesis of smoking-induced airway diseases (Aguayo 
1994b). In addition, some papers have also reported increased urinary levels of NE 
peptides in smokers or smoking-related airway obstruction (Aguayo et al. 1989; 
Aguayo et al. 1992a; Meloni et al. 1998). In paper I, we report for the first time 
circulating levels of the general NE marker CgA according to the smoking habits, lung 
function and respiratory symptoms. Among the selected subjects from the HUNT study, 
we observed significantly higher levels of serum CgA in male smokers with airway 
obstruction than in smokers with normal lung function and in never-smokers. In 
addition, respiratory symptoms were associated with elevated CgA levels in male 
smokers. Among females, these differences were not significant. Using multiple linear 
regression analysis, age, lung function and serum creatinine were statistically significant 
predictors of CgA in males, accounting for 25% of the variability of CgA.  
 
In paper I, all data were stratified by sex. This revealed a different pattern of CgA levels 
between the gender according to smoking habits, lung function and respiratory 
symptoms. However, results after including the interaction terms ((FEV1% x sex) and 
(pack-years x sex)) in a non-stratified multiple linear regression model did not support 
the thought of an interaction of sex on the serum CgA. One possible explanation for the 
apparently sex difference in the analyses may be the small number of females in some 
of the study groups.  
 
Another finding in paper I was the increasing levels of CgA with decreasing lung 
function and elevated levels of CgA in smokers with respiratory symptoms and chronic 
bronchitis. This indicates that increased CgA levels observed in paper I may be related 
to lung disease and inflammation, and not to pharmacological or toxic effects of 
nicotine or cigarette smoke alone.  
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Based on the results of paper I, it may be suggested that the pulmonary NE system plays 
a role in some airway diseases. This paper does not allow us to confirm the origin of 
elevated circulating levels of CgA. As discussed in paper I, the higher circulating CgA 
levels in smokers with airway obstruction or in subjects with respiratory symptoms and 
chronic bronchitis may reflect either a local secretion from the lungs or a general NE 
activation. Hypothetically, PNEC/NEBs hyperplasia associated with airway 
inflammation may increase the serum levels either as increased number of NE cells 
(constitutive pathway) or as increased release from pulmonary NE cells (regulatory 
pathway). Increased levels of NE peptides, such as BLPs have previously been found in 
bronchioalveolar lavage fluid from smokers compared with non-smokers (Aguayo et al. 
1989). However, severe airway obstruction like COPD, which is considered a systemic 
disease (Wouters 2002), may also lead to a general NE activation. A comparable 
situation may be patients with chronic heart failure, where elevated circulating levels of 
CgA are reported (Ceconi et al. 2002).  
 
In conclusion, elevated serum CgA levels in subjects with airway obstruction and 
respiratory symptoms may represent NE activation in inflammatory or remodelling 
processes in the respiratory organs. 
 
6.1.2. Effects of chronic inhalation of CO on 
            the respiratory and cardiovascular system 
Chronic CO inhalation, at exposure levels comparable to heavy smokers, may have 
important effects on health. However, few long-term exposure studies have been 
published (Stupfel & Bouley 1970; Turner et al. 1979), and no information exists of 
chronic CO inhalation and effects on the respiratory morphology and pulmonary NE 
cells. In paper II, the effects of long-term CO exposure were evaluated in rats, with 
particular emphasis on morphological findings in the respiratory organs and the 
cardiovascular system. 
 
The results from the exposure study show that chronic inhalation of CO does not appear 
to induce morphological changes in the lung of rats. The respiratory pathology usually 
associated with cigarette smoking, such as emphysema, inflammation or remodelling of 
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the parenchyma, were absent in the present study (paper II). The same conclusion was 
made by Hugod in a short-term study of adult rabbits exposed to 200 ppm for 6 weeks 
(1980). However, another study by Penney et al. has reported an increase in lung weight 
in rats exposed to 250-1300 ppm for 7.5 weeks, which was not explained by specific 
morphological changes (1988). This finding was not confirmed in our study. 
 
Experimental exposure studies of different gases have previously shown morphological 
changes in the pulmonary NE system. An increase in the number of PNEC and NEBs is 
reported in response to chronic high concentration of oxygen, ozone and non-filtered 
urban ambient air (Schuller et al. 1988; Ito et al. 1989; Ito et al. 1994). Furthermore, 
some studies have linked cigarette smoking to changes in the pulmonary NE system. 
Components of tobacco smoke are reported to have trophic effects on pulmonary NE 
cells (Novak et al. 2000). However, even though NEBs may exhibit a potential binding 
site for CO through the NADPH-oxidase, no difference in number of NEBs was 
observed between the groups in the present study (paper II). Chronic CO inhalation did 
not affect the pulmonary NE cells in a way detected by current morphological 
evaluation. We may therefore conclude that other components of the tobacco smoke 
than CO are responsible for changes in the pulmonary NE system.  
 
On the other hand, recent studies have reported several favourable effects of low-dose 
CO inhalation. CO may have cytoprotective effects in acute lung injury and lung 
fibrosis (Otterbein et al. 1999; Sato et al. 2001). In addition, CO inhalation seems to 
decrease airway hyperresponsiveness in mice models (Ameredes et al. 2003). Whether 
these effects of CO on pathological conditions are mediated via changes in the 
pulmonary NE cells are not known. Our study was not designed to investigate possible 
protective effects of CO on pathological processes.  
 
Some previous studies have proposed a link between CO exposure and cardiovascular 
diseases (Astrup et al. 1967; Stern et al. 1988; Burnett et al. 1997; Melin et al. 2005). 
However, the evidences are inconsistent. In the present study (paper II), CO exposure 
for 72 weeks did not lead to any morphological changes in the cardiovascular system, 
except for cardiac hypertrophy. Histological examination of the myocardium did not 
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reveal any signs of scarring, which could indicate previous myocardial infarction. In the 
aorta and femoral artery, no signs of atherosclerosis were observed in CO exposed rats. 
The mechanisms for cardiac hypertrophy in CO exposed animals, which has been 
reported by several authors (Penney et al. 1984; Clubb et al. 1986; Loennechen et al. 
1999), are not completely known. One hypothesis is that ventricular hypertrophy results 
from an increase in volume overload due to blood volume and viscosity enhancement 
and increased ventricular preload. However, it may also be proposed that CO may have 
some direct effects on the myocardium. In a sub-study of paper II (Bye et al., submittet 
2007), cellular analyses showed both longer and wider cardiomyocytes in the CO 
exposed animals. In addition, several regulatory proteins associated with pathological 
cardiac hypertrophy were up-regulated suggesting intrinsic effects of CO on the 
myocardium. This is also supported by the fact that CO, like NO, is regarded as a 
cellular signal molecule (Kim et al. 2006). 
 
6.2. The pulmonary NE system and tumourigenesis 
 
6.2.1. Chronic inhalation of CO and tumourigenesis 
Inhalation of cigarette smoke is the main etiological agent of lung cancer (Hutt et al. 
2005). Experimental studies have shown that several compounds of tobacco smoke, like 
polycyclic aromatic hydrocarbons and nitrosamines are associated with cancer in the 
respiratory organs (Hecht 2002). However, little is known about the effects of long-term 
CO exposure on induced or spontaneous tumourigenesis. In the present study (paper II), 
we could not detect any carcinogenic effects of inhalation of CO at doses corresponding 
to tobacco smoking with an exposure time of three quarters of the rats life expectancy. 
No difference of the overall tumour prevalence was detected between the groups. Only 
one lung tumour (an adenocarcinoma) was observed. Even though this tumour was 
observed in the CO exposed group, the finding could be accidental. In addition, one 
papillary NE hyperplasia was observed in each of the study groups.  Another study by 
Ito et al. reported bronchial papillomas with NE differentiation in rats exposed to 
polluted ambient air for 18 months (1989). However, this study did not include a control 
group for comparison and CO level in the ambient air was not measured. Furthermore, 
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in the present study (paper II), no increased number of PNEC or NEBs was observed. 
Therefore, our findings of papillary NE hyperplasia may represent a normal 
spontaneous occurrence in aged rats. Taken together, the present exposure study did not 
support any idea of a tumourigenetic effect of CO in rats. 
 
6.2.2. NE markers in non-small cell lung cancer 
In paper III, we report the expression of NE markers in 20 cases of NSCLC using 
biochemical, IHC and ultrastructural methods. The results of IHC evaluation of the NE 
markers NSE, SYN, CgA and NCAM showed a wide variation in the immunoreactivity. 
The proportion of immunoreactivity ranged from only 5 % with CgA to 50 % with NSE 
using conventional methods. Adding the tyramide signal amplification technique, the 
number of immunoreactive cases increased significantly for CgA and SYN. With the 
use of immunoelectron microscope only one of 15 representative tumours showed 
ultrastructural immunolabelling for CgA in cytoplasmic vesicles.  
 
These findings illustrate some of the problems in assessing the differentiation of a 
tumour. The formation of a tumour involves several steps from a genetically disturbed 
cell into uncontrolled growth of cells (Alberts 2002). During these steps the cell of 
origin often looses its characteristics and may be difficult to recognise in clinically 
presented tumours. The ability to detect the general NE marker CgA for instance, is 
directly related to the number of secretory vesicles in the cytoplasm. Tumours with 
small number of vesicles may therefore show no immunoreactivity for CgA using 
conventional IHC methods. However, amplification of the IHC signals may increase the 
sensitivity, as shown in the present study (paper III) with the use of tyramide signal 
amplification technique. Even though no “gold standard definition” of NE 
differentiation exists, ultrastructural finding of CgA labelled vesicles in the tumour cells 
represents a strong hallmark for NE differentiation. In the present study (paper III) only 
one of five IHC positive CgA tumours showed immunogold labelling of the DCV, 
which may be explained by sampling errors in ultrastructural analyses. In a comparable 
study on SCLC, which is a well defined NE tumour, Dardick et al. reported only three 
immunogold labelled tumours of 15 CgA IHC positive tumours (1996). Taken together, 
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ultrastructural evaluation with IEM does not seem to increase the sensitivity of NE 
differentiation compared to sensitive IHC techniques. 
 
It has been argued that looking for NE differentiation in NSCLC is only of academic 
interest since the clinical significance of NE differentiation is disputable. The current 
opinion is that the finding of NE features in NSCLC does not influence prognosis or 
response to treatment (Hiroshima et al. 2002; Pelosi et al. 2003; Howe et al. 2005; 
Ionescu et al. 2007). However, paper III illustrates some important aspects regarding the 
role of pulmonary NE cells in carcinogenesis and tumour classification for future 
therapeutic modalities. 
 
Even though lung cancer is one of the most common neoplasms, the exact cell of origin 
of the different histological types of lung cancer is not well understood. As described in 
section 3.5.1, some preneoplastic changes are suggested, which is mainly based on 
histological findings associated with resected carcinomas of the lung. In addition, 
accumulations of genetic abnormalities have been found in correlation with increasing 
morphological changes (Hirano et al. 1994; Greenberg et al. 2002). However, in 
smokers, who in particular are at risk, often several different preneoplastic changes are 
seen at the same time at different locations (lung “field cancerisation”) (Greenberg et al. 
2002). 
 
The finding of NE markers in non-NE tumours (paper III) may suggest that the NE cells 
of the lung are the cellular origin of the NE differentiated lung carcinomas. NE cells are 
multipotent cells with the ability to divide, and may differentiate into many types of 
cells (Sunday & Willett 1992). Classical NE tumours of the lung have been, according 
to their NE features with positive NE markers and DCV, proposed to originate from NE 
cells in the bronchial mucosa (Kerr 2001). The findings in the present study of NE 
features of NSCLC (paper III) may suggest an origin from the same cells. It can be 
hypothesised that NSCLC with NE characteristics rather are de-differentiated NE 
lesions than tumours with NE differentiation. Furthermore, in gastric carcinogenesis, 
some studies have proposed that the NE enterochromaffin like cell (ECL cell) in the 
stomach may be the origin of gastric adenocarcinomas (Waldum et al. 1998). Both 
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human observations and experimental animal studies have suggested the principle of 
NE cell de-differentiation in tumourigenesis (Qvigstad et al. 1999; Fossmark et al. 
2004; Fossmark et al. 2005b). On the other hand, lung cancers often show a 
heterogeneous histology with a mixture of subtypes, including both SCLC and NSCLC 
(Brereton et al. 1978). This may also suggest that some lung carcinomas may be derived 
from a common endodermal stem cell with potential of multidirectional differentiation 
(Brambilla et al. 2000). 
 
Finally, knowledge of the expression of various NE markers in NSCLC may have 
implications for future therapy. Increasingly experimental and clinical use of molecular 
targeted therapy with drugs targeting important molecules involved in different steps in 
the neoplastic transformation of cells may necessitate further sub-classification using 
various markers (Ho et al. 2005; Janson 2005; Maione et al. 2006). This may give 
additional information concerning prognosis and response to new therapeutics. In the 
future, lung cancer treatment may be individually adjusted according to a set of markers 
including different NE markers.  
 
6.3. The pulmonary NE system and the physiological hypoxic response 
 
In order to maintain a well balanced ventilation and perfusion in the lung, different 
homeostatic reactions to low oxygen levels are observed in the respiratory organs (von 
Euler 1946). It is proposed that several systems and cells are involved in the hypoxic 
response of the airways and pulmonary vasculature, including the pulmonary NE 
system (Gosney 1994; Dumas et al. 1999; Jain & Sznajder 2005). In paper IV, we have 
evaluated the effects of intermittent alveolar hypoxia on the pulmonary NE system. 
Using an isolated buffer-perfused and ventilated rat lung model, release of the NE 
products BLPs and serotonin into the pulmonary circulation during IH was examined. 
The findings revealed that during the first periods of IH, levels of BLPs in the perfusate 
gradually decreased. Even though a lot of knowledge exists about the functions of 
bombesin and BLPs (Willey et al. 1984; Sunday et al. 1990; Lemaire 1991), little is 
known about the effects of alveolar hypoxia on the pulmonary release of BLPs. In the 
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respiratory system, immunoreactivity for BLPs is found mainly in the pulmonary NE 
cells (Aguayo et al. 1990) and in some GRP containing nerve fibres (Uddman et al. 
1984). Levels of BLPs in the pulmonary circulation may therefore correspond to 
changes in the pulmonary NE system.  
 
Given the proposed effects of NEBs to sense the alveolar oxygen contents (Cutz & 
Jackson 1999), the finding of decreased levels of BLPs during intermittent hypoxia 
illustrates some important aspects of the function of the pulmonary NE system. Even 
though alveolar hypoxia is associated with membrane depolarisation and release of 
vesicle contents from the pulmonary NE cells (Cutz et al. 2003), this reaction may be 
modified by local actions. By autocrine, paracrine or neurocrine feedback mechanisms 
the NE cells may adjust the release of products to suit the appropriate physiological 
response. In this regard, reduced levels of BLPs, which among other functions act as 
bronchoconstrictors (Impicciatore & Bertaccini 1973), may results in a 
bronchodilatation in order to maintain adequate ventilation. This is also supported by 
another study by Helset et al. showing decreased release of the vasodilator CGRP in the 
perfusate of blood-perfused rat lungs ventilated with hypoxic gas (1995).  
 
In paper IV, we did not find any association between the release of serotonin and IH. 
During the experiment the levels of serotonin detected in the perfusate varied 
considerably at different periods in both groups. In an experimental study of dogs, 
Yemen et al. reported increased levels of serotonin in blood-samples from the left 
ventricle during hypoxic ventilation (2003). In addition, a recent in vitro study has 
shown release of serotonin from intact rabbit NEB cells during hypoxia (Fu et al. 2002). 
The results from paper IV did not confirm these findings. However, this may have some 
methodological explanations. Additional sources of serotonin may have masked the 
hypoxic serotonin response from the pulmonary NE cells, like serotonin stored in 
platelets (Omenn & Smith 1978) and pulmonary mast cells (Aldenborg et al. 1993) in 
addition to neurotransmitter-release from neurons.  
 
Increased number of pulmonary NE cells has been described in association with 
hypoxia in both experimental animal studies and human pathologic reports (Keith & 
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Will 1981; Johnson et al. 1982; Gosney et al. 1989; Aguayo et al. 1990; Aguayo 1993, 
1994a). This has most often been ascribed to hyperplasia of NEBs/PNEC, either as a 
primary pathological event or as a secondary response to low levels of oxygen (Aguayo 
1994a). However, changes in the intercellular level of bioactive substances and thereby 
the immunoreactivity for antibodies may occur rapidly. In paper IV, we report an 
increase in number of CGRP immunoreactive NEBs in lungs ventilated for only 40 min 
with IH compared to normoxic ventilated lungs. This finding is supported by other 
studies showing increased CGRP immunoreactive pulmonary NE cells in rats exposed 
to ambient hypoxia for 4 hours (Roncalli et al. 1993), and an observation of decreased 
levels of CGRP in blood from isolated perfused rat lungs ventilated with intermittent 
hypoxic gas for 5 min (Helset et al. 1995). Together, this support the idea that hypoxia 
leads to decreasing release and thereby an up-concentration of CGRP in the NEBs, 
rendering more cells detectable with IHC methods. 
 
Finally, using antibodies to the general NE marker CgA, only a few NEBs/PNEC were 
detected in the present study. In contrast to the expression of CGRP, no difference in the 
number of CgA immunoreactive pulmonary NE cells between the IH ventilated lungs 
and the controls was observed. Again, this suggests that the hypoxic response of the 
pulmonary NE cells may be complex and involves specific reactions for the actual NE 
product.  
 
In conclusion, the results from paper IV indicate a rapid response to intermittent 
alveolar hypoxia on the release of some NE products in isolated buffer-perfused rat 
lungs. This further suggests that the pulmonary NE system may play a role in order to 
maintain a well balanced ventilation and perfusion relationship in the lung.  
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7. Main conclusions 
 
1. Serum levels of CgA  
• are increased in male smokers with airway obstruction compared to non-
smokers and smokers with normal lung function 
• are correlated to the degree of airway obstruction in men 
• are associated with the presence of respiratory symptoms and chronic bronchitis 
 
2. Chronic inhalation of CO in rats at levels corresponding to tobacco smoking  
• induces right and left ventricular hypertrophy 
• does not lead to increased atherosclerosis 
• is not associated with tobacco smoking related pathology of the respiratory 
system 
• has no impact on the morphology of pulmonary NE cells 
• has no tumourigenic effects 
 
3. Evaluation of NE markers in NSCLC demonstrated that 
• using sensitive IHC methods, like the tyramide signal amplification technique, a 
greater proportion of NE differentiated tumours was detected 
• IEM methods with immunogold-labelling of CgA were not as sensitive for 
detection of NE features as IHC techniques with signal amplification 
• levels of circulating CgA or NSE did not correlated to positive IHC findings 
 
4. Evaluation of NE products in isolated perfused and ventilated rat lung revealed   
• a decreased release of BLPs in perfusate from lungs intermittently ventilated 
with hypoxic gas compared to normoxic controls 
• a release of serotonin in lung perfusate independent of hypoxic or normoxic 
ventilation 
• an increase in CGRP immunoreactive NE cells in hypoxic ventilated lungs 
• no difference in number of CgA immunoreactive NE cells between hypoxic and 
normoxic ventilated lungs 
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Together, the findings presented in this thesis have elucidated some important aspects of 
the pulmonary NE system in man and rodents. The thesis suggests that the NE system 
of the lung may play a role in pathological conditions like inflammatory or remodelling 
processes in the respiratory organs, in the tumourigenic process of the lung and in 
physiological adaptations such as for instance hypoxia. In addition, the results indicate 
that environmental substances such as CO do not have any impact on the pulmonary NE 
cells. However, the basic mechanisms behind the changes in the NE cells in different 
conditions are still not known. Further studies are needed, especially on the role of 
PNEC/NEBs in inflammatory lung diseases and pulmonary carcinogenesis.  
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Abstract
Carbon monoxide (CO) is a dangerous poison in high concentrations, but the long-term effects of low doses of CO, as in the
gaseous component of tobacco smoke, are not well known. The aims of our study were to evaluate the long-term effects of inhaled
CO on the respiratory and cardiovascular system at doses corresponding to tobacco smoking and its effect on tumourigenesis and
pulmonary neuroendocrine (NE) cells. Female Wistar rats were exposed to either CO (200 ppm) for 20 h/day (n = 51) or air (n = 26)
for 72 weeks. Carboxyhaemoglobin was 14.7 ± 0.3% in CO exposed animals and 0.3 ± 0.1% in controls. In the lungs, no signs of
pathology similar to that associated with cigarette smoking were observed, and no differences in number of pulmonary NE cells
were observed between the groups. Chronic CO inhalation induced a 20% weight increase of the right ventricle (p = 0.001) and
a 14% weight increase of the left ventricle and interventricular septum (p < 0.001). Histological examination of the myocardium
did not reveal any signs of scarring. In the aorta and femoral artery, no signs of atherosclerosis were observed in CO exposed rats.
No exposure related carcinogenic effects were observed. Spontaneous tumours were identified in 29% of CO exposed animals and
in 28% of the controls. Our results suggest that low dose CO exposure is probably not responsible for the respiratory pathology
associated with tobacco smoking. The effects on the cardiovascular system seem to involve myocardial hypertrophy, but not
atherogenesis.
© 2006 Elsevier Ireland Ltd. All rights reserved.
Keywords: Carbon monoxide; Cardiac hypertrophy; Lung; Pulmonary neuroendocrine cells; Tobacco smoke; Tumourigenesis
Abbreviations: CGRP, calcitonin gene related peptide; CO, carbon monoxide; COHb, carboxyhaemoglobin; COPD, chronic obstructive lung
disease; EM, electron microscope; Hb, haemoglobin; HO, heme oxygenase; IHC, immunhistochemistry; LV, left ventricle; LV + S, left ven-
tricle + interventricular septum; NE, neuroendocrine; NEB, neuroepithelial body; PBF, phosphate-buffered formalaldehyde; PNEC, pulmonary
neuroendocrine cells; ppm, parts per million; RV, right ventricle; S.E.M., standard error of mean; TBS, Tris-buffered saline
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. Introduction
Cigarette smoking is one of the most important eti-
logic factors of diseases in the respiratory and car-
iovascular system. The mechanism of the detrimental
ffects of cigarette smoke involves several mediators and
athways. Cigarette smoke is composed of hundreds
f chemicals, including tar with its many carcinogens,
icotine, free radicals and gaseous compounds, such as
arbon monoxide (CO). The gas component of cigarette
moke contains 4.5% CO, and the CO concentration of
nhaled cigarette smoke may reach as high as 500 parts
er million (ppm) (WHO, 1999). Smoking increases car-
oxyhaemoglobin (COHb) levels from 1 to 2% in non-
mokers up to 15% in heavy smokers (Omaye, 2002).
ome studies have also reported elevated COHb levels in
on-smokers exposed to environmental tobacco smoke
Scherer et al., 1990).
CO is considered a toxic chemical at high concen-
rations, leading to a severe hypoxic condition by dis-
lacing oxygen from haemoglobin (Hb), leftward shift
f the oxyhaemoglobin dissociation curve, and binding
o intracellular enzymes. However, several reports indi-
ate that even low levels of chronic CO exposure may
ave important effects on health. Epidemiological stud-
es have shown that ambient CO levels correlate with
nset of heart diseases, increased mortality rates, and
ospital admission for cardiovascular diseases (Stern et
l., 1988; Kleinman et al., 1989; Burnett et al., 1997). In
ddition, recent animal studies have shown that inhala-
ion of CO at doses corresponding to tobacco smoking
orsens cardiac failure both in rats with experimen-
al myocardial infarction and pre-existing hyperthrophic
ardiomyopathies (Melin et al., 2005; Mirza et al., 2005).
urthermore, CO exposure has been suggested as an
mportant etiological factor for atherosclerosis (Astrup
t al., 1970; Kleinman et al., 1989). However, these find-
ngs have been questioned by other experimental studies,
hich did not show any association between CO expo-
ure and atherosclerotic diseases (Weir and Fabiano,
982; Penn et al., 1992).
Effects of acute high dose CO exposure on the respi-
atory system are well known, including pulmonary cell
amage, endothelial and alveolar swelling and oedema
Niden and Schulz, 1965). Conversely, little epidemio-
ogical and experimental information is available on the
ulmonary effects of long-term low dose CO exposure.
obacco smoke is the main source of CO exposure in the
eneral population. Therefore, many respiratory effects
f CO may be confounded by the effects of tobacco
moke, which includes chronic obstructive pulmonary
isease (COPD) and lung cancer.228 (2006) 280–290 281
An association between cigarette smoking and hyper-
plasia of a subgroup of airway epithelial cells called
pulmonary neuroendocrine cells (PNEC), has been pos-
tulated by some authors (Gosney et al., 1989; Aguayo,
1994). These cells, which belong to the diffuse neuroen-
docrine (NE) system, are located among other epithe-
lial cells in the airways, either as solitary PNEC or as
aggregates of NE cells known as neuroepithelial bod-
ies (NEBs). The function of the pulmonary NE system
is not completely known, but it may be important in
control of growth and development of the foetal lung.
In addition, it may contribute to regulation of venti-
lation and circulation in the postnatal and adult lung
(for review, see Van Lommel, 2001). NEBs have a
rich innervation, and are hypothecated to be specialised
chemoreceptors, responsible for detecting the alveolar
oxygen levels (Cutz and Jackson, 1999). It has been pro-
posed that CO, through binding to the oxygen receptor,
may interact with the pulmonary NE system (Haddad,
2002).
To our knowledge, only a few experimental long-
term studies with low levels of CO exposure have
been published (Stupfel and Bouley, 1970; Armitage
et al., 1976; Turner et al., 1979). However, the results
are conflicting, and no information exists of long-term
effects of CO inhalation on the pulmonary morphol-
ogy and tumourigenesis. Therefore, a 72 weeks exper-
iment was performed on female rats to study inhaled
CO exposure at levels comparable to heavy smokers.
The main aims of the study were to investigate the
effects of chronic CO exposure in vivo, with particular
emphasis on the respiratory and cardiovascular system,
including pulmonary NE cells and a possible effect on
tumourigenesis.
2. Materials and methods
2.1. Animals
Outbred 6–8 weeks old female Wistar rats (Harlan Nether-
lands B.V., The Netherlands) with an initial weight of
169 ± 4.5 g (mean ± S.E.M.) were exposed to either CO
(n = 51) or air (n = 26). The animals were caged in groups of
six or seven. They were fed a pellet rodent diet (RM1, Special
Diets Services, Essex, England) available 4 h a day (8:00 a.m. to
12:00 noon), 5 days a week and with free access to food through
the weekends. Tap water was provided ad libitum. Light was
controlled in a 12:12-h light–dark cycle. Bedding was changed
two times a week. The rats were weighed monthly. The study
was approved by the Norwegian Council for Animal Research
and conformed to the “European Convention for the Protec-
tion of Vertebrate Animals Used for Experimental and Other
Scientific Purposes”.
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2.2. CO exposure
Four animal steel cages were placed in each of three
650 l stainless steel and glass chambers designed as a cube
with a conical top and bottom, as described in a previous
study (Waldum et al., 1994). The positions of the cages in
the chambers were changed systematically. A mixture of
hospital medical quality air and CO (AGA, Oslo, Norway)
was continuously circulated through two of the chambers. An
airflow of 165 l/min and a CO flow of 0.03 l/min created a CO
concentration of 200 ppm and about 15 air changes/h in the
inhalation chambers. Pure hospital medical quality air was
circulated through the control chamber, at equal rate to the two
CO exposed chambers. The CO concentration was monitored
daily by a gas monitor (NEOTOX XL single-gas monitor,
Neotronics, UK) and no statistical differences were measured
between the two CO exposure cambers (202 ± 1.7 ppm versus
199 ± 1.6 ppm). No CO was detected in the control chamber.
The animals were CO exposed for 20 h a day (12:00 noon
to 8:00 a.m. the following day), 5 days a week (Monday to
Friday) for 72 weeks. Temperature in the three chambers (two
CO exposure and one control) was 23.0 ± 0.1, 22.8 ± 0.1
and 22.9 ± 0.2 ◦C and with a relative humidity of 71.6 ± 1.0,
71.3 ± 1.1 and 64.1 ± 1.0%, respectively.
2.3. Animal procedures and tissue preparation
Before start of exposure, some animals from the CO expo-
sure group (n = 8) and controls (n = 8) were anaesthetised with a
subcutaneously injected mixture of fentanyl 12.5g/ml, mida-
zolam 1.25 mg/ml and haloperiodol 0.83 mg/ml (0.4 ml/100 g
rat weight), before collecting blood from the saphenous vein.
After 2 weeks of exposure, two CO exposed rats and one
control rat were sacrificed after anaesthesia, and blood col-
lected by puncture of the abdominal aorta for determination of
COHb levels. The animals were taken directly from the expo-
sure chambers before the sacrifice.
After 3 months exposure, eight rats from each chamber
(n = 24) were anaesthetised and blood sampled from the saphe-
nous vein. At 6 months exposure, two animals from each cham-
ber were anaesthetised, sacrificed and examined for pathology.
Throughout the exposure period, animals exhibiting signs of
illness were removed from the chambers, anaesthetised, sacri-
ficed and examined.
At the end of the study (72 weeks of exposure) the remaining
animals (CO exposed; n = 42, control; n = 22) were anaes-
thetised, and killed with blood-drawing from the abdominal
aorta. Blood samples were collected in heparin-coated tubes
and placed on ice until analysed. COHb and Hb levels were
measured in an ABL SYSTEM 625 spectrophotometer (Dia-
mond Diagnostics, USA) within 3 h of sampling. The animals
were examined for macroscopic pathology of the brain, lungs,
heart, thoracic aorta, femoral artery, gastrointestinal (GI) tract,
liver, spleen, kidneys, ovaries and urinary bladder. In addition,
weight of the lungs, stomach, liver, spleen, kidneys, ovaries
and urinary bladder were measured. The hearts were incised
at the level of the valves, and the left ventricle (LV) together228 (2006) 280–290
with the interventricular septum (LV + S) was dissected free
from the right ventricle (RV) and weighed. Each ventricle
was sectioned coronarily, fixed in 4% phosphate-buffered for-
malaldehyde (PBF), and dehydrated in 80% ethanol, before
embedding in paraffin for histological analyses. In addition,
tissue samples from the thoracic aorta and femoral artery were
collected and fixed in 4% PBF. The lungs were dissected free
from the heart, greater vessels, and oesophagus, and weighed.
The left lung was carefully filled intrabronchially with 1.5 ml
4% PBF and immersed in 4% PBF overnight before dehydra-
tion in 80% ethanol. Thereafter, the lung was sectioned into
four slices from the hilus, perpendicular to the main bronchus,
and embedded in paraffin. In addition, blocks of 1 mm3 lung
tissue from some animals were fixed in 2.5% glutaraldehyde
for electron microscopy (EM).
2.4. Histopathologic evaluation
Paraffin embedded tissue was cut in 4m thick sections,
mounted on slides (Super Frost® Plus, Braunschweig, Ger-
many) and stained with regular haematoxylin and eosin (H&E).
The tumours were classified according to the most compa-
rable human terminology, based on H&E sections. Sections
were examined for visible microscopic pathology, described
in Table 1, and the degree of inflammation was calculated as
number of sectioned airways with an adjacent lymphoid follicle
divided by the total number of airways of the section. In addi-
tion, four lung sections from each study group were stained
using the Elastica van Gieson staining kit (Merck KGaA,
Darmstadt, Germany) for evaluation of pulmonary hyperten-
sion, as described by Keegan et al. (2001). Pulmonary arteries
(25–100m external diameter) associated with an airway were
counted and considered muscularized, if possessing a distinct
double-elastic lamina, visible for at least half of the vessel cir-
cumference in a cross section.
2.5. Immunohistochemistry
Lung sections for immunohistochemistry (IHC) were de-
waxed with xylene, rinsed in graded alcohol, re-hydrated in
water and immersed in 3% hydrogen peroxide for 10 min to
block endogenous peroxidase activity. Antigen retrieval was
achieved by heating the sections in 10 mM Tris–EDTA (pH
9.0) in a commercial microwave oven at 160 W for 15 min. For
visualisation of pulmonary NE cells, sections were incubated
with polyclonal anti-calcitonin gene related peptide (CGRP)
(diluted 1:12,000, L-8198, Sigma–Aldrich, St. Louis, MO,
USA) for 60 min at room temperature. The antibodies were
diluted in Tris-buffered saline (TBS, pH 7.4) with 0.025%
Tween 20 (DakoCytomation, Glostrup, Denmark) and 1%
bovine serum albumin (BSA, Sigma, St. Louis, MS). Between
each step, the sections were washed in TBS with 0.05% Tween
20. The immunoreactivity was visualised with an Envision-
HRP kit (K5007, DakoCytomation, Glostrup, Denmark) and
DAB+ (K4065, DakoCytomation, Carpinteria, CA, USA). All
sections were finally counterstained with haematoxylin for 6 s.
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Table 1
Morphological signs of respiratory and cardiovascular pathology
Emphysema Enlargement of the alveolar spaces or destruction of alveolar septal tissue
Inflammation Accumulation of inflammatory cells in airways, alveoli or in the parenchyma
Increased fraction of airways associated with lymphoid follicles
Bronchial/peribronchial thickening Increased epithelium layer, bronchial muscle hypertrophy or submucosal gland enlargement
Fibrosis Increased collagen deposit (Elastica van Gieson staining)
Pulmonary hypertension Fibrotic thickening of the lamina interna and hypertrophy of the muscular lamina media of the
pulmonary arteries (H&E staining)
Increased muscularized small arteries with a double elastic lamina (Elastica van Gieson
staining)
Atherosclerotic lesion Accumulation of foam macrophages, proliferation of myointimal cells, fibrosis, inflammation
the lam
M nulatio
i
a
c
o
o
r
n
T
o
s
M
2
m
i
d
a
t
u
l
w
a
T
b
o
G
2
(
d
t
b
(
a
3.2. Effects of CO on COHb and Hb
During the study, levels of COHb and Hb were mea-
sured in the animals (Table 3). In CO exposed animals,or destruction of
yocardial scarring Fibrovascular gra
PNEC and NEBs were identified as clear positive
mmunoreactive cells with a stained cytoplasm located within
ll levels of the respiratory tree down to the respiratory bron-
hioles. The locations of the NEBs were classified into alve-
lobronchiolar (aNEBs) (located in respiratory bronchioles
r alveoli) and bronchiolar/bronchial (bNEBs), and the size
eported as number of immunoreactive cells with a visible
ucleus. In addition, single PNEC in the airways were counted.
otal number of NE cells/NEBs was divided by the total area
f the section. The area was calculated from photos of the lung
ections using iTEM Analysis (Soft Imaging System GmbH,
u¨nster, Germany) software.
.6. Electron microscopy
Lung tissue from two CO exposed and two control ani-
als were immersed in 2.5% glutaraldehyde and post-fixed
n 2% osmium tetroxide for 60 min, before the samples were
ehydrated in a graded series of ethanol and propylene oxide
nd embedded in epoxy resin LX 112 (Ladd Research Indus-
ries, Willinton, VT, USA). The samples were further sliced in
ltra-thin sections (70 nm, RMC MTX Ultramicrotom, Boeck-
erand) and mounted on copper grids, before being contrasted
ith uranyl acetate and lead citrate. The grids were examined in
JEOL 1011 (Tokyo, Japan) transmission electron microscope.
he thickness of the fused basal membrane of the air-blood
arrier was measured at 12 locations along the alveolar wall
f each animal using iTEM Analysis (Soft Imaging System
mbH, Mu¨nster, Germany) software.
.7. Statistical analysis
Data are presented as means ± standard error of mean
S.E.M.). Differences between groups of normally distributed
ata were analysed using Student’s t-test and ANOVA for mul-
iple comparison. The χ2-test was used to compare differences
etween proportions. Statistical significance was set at p < 0.05
two-sided). All data were analysed using the statistical pack-
ge for social sciences (SPSS, version 13.0, Chicago, IL, USA).ina elastica interna in systemic arteries
n tissue and fibrosis
3. Results
3.1. Effects of CO on animal and organ weights
There was not observed any difference in the weight
gain between CO exposed and control animals during
the study period, as shown in Fig. 1. At the end of
the study, the CO exposed group had a mean body
weight of 275 ± 4 g compared to 270 ± 6 g in the control
group (p = 0.544). Specific organ weights are provided in
Table 2, showing that the only difference between the CO
exposed and control groups was seen on cardiac weights
(described in Section 3.4.1).Fig. 1. No difference was observed in animal weight gain during the
72 weeks exposure period between CO exposed and control rats. The
data are presented as cumulative mean rat weight gain corrected for
decreasing number of animals with time.
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Table 2
Organ weights
Organ CO exposed Control
Lung (mg) 1416 ± 26.6 1387 ± 29.8
RV (mg) 134 ± 3.2* 112 ± 5.2
LV (mg) 642 ± 12.4* 561 ± 14.7
RV/BW (mg/g) 0.48 ± 0.01* 0.42 ± 0.02
LV/BW (mg/g) 2.33 ± 0.03* 2.09 ± 0.04
RV/LV 0.21 ± 0.01 0.20 ± 0.01
Stomach (mg) 1900 ± 21.4 1890 ± 52.2
Liver (g) 7.05 ± 0.16 6.57 ± 0.22
Kidneys (mg) 1667 ± 25.6 1622 ± 34.3
Urinary bladder (mg) 90 ± 2.8 86 ± 4.1
Ovaries (mg) 121 ± 4.5 121 ± 6.4
Spleen (mg) 691 ± 75.0 557 ± 23.1
No. of animals 43 23Data are presented as: no., numbers and means ± S.E.M. RV: right
ventricle; LV: left ventricle; BW: body weight. *p ≤ 0.001 vs. control
group.
COHb levels ranged from 11.0 to 14.7%. COHb lev-
els in control animals were <0.3%. Similarly, Hb levels
were increased in the CO exposed animals compared
to control animals from 12 weeks exposure time and
throughout the study.
3.3. Effects of CO on the respiratory system
3.3.1. Morphology
H&E stained sections of the lungs did not reveal
any of the morphological signs of smoking associated
pathology summarised in Table 1. No distinct morpho-
logical differences between the CO exposed and con-
trol animals were observed. The fraction of airways
with an associate lymphoid follicle was not statistically
different between the CO exposed and control group
(14.0 ± 1.6% versus 15.1 ± 1.7%, p = 0.664) (Fig. 3D).
Furthermore, no ultrastructural differences in alveo-
lar epithelial cells or alveolar septas between the two
groups were observed with the use of EM (Fig. 2).
Table 3
Blood levels of carboxyhaemoglobin (COHb) and haemoglobin (Hb)
Time (weeks) COHb (%)
CO exposed n Control n
0 – –
2 11.0 ± 1.0 2 0.1 1
12 – –
24 12.6 ± 0.7 4 0.1 ± 0.1 2
72 14.7 ± 0.3* 43 0.3 ± 0.1 22
Data are presented as means ± S.E.M. *p < 0.02 vs. control group.228 (2006) 280–290
The thickness of the fused basal laminas of the alveolar
epithelial and endothelial cells of the blood-air barrier
did not differ significantly between CO exposed and
control animals (89.21 ± 2.6 nm versus 85.22 ± 2.2 nm,
p = 0.252).
3.3.2. Pulmonary neuroendocrine cells
Chronic CO exposure was not associated with
any significant morphological changes in the pul-
monary NE system. The number of single PNEC
immunoreactive for CGRP (Fig. 3A) in the airway
epithelium was slightly higher in CO exposed animals
compared to control animals, but without a statisti-
cally significant difference (1.9 ± 0.2 cells/cm2 versus
1.7 ± 0.3 cells/cm2, p = 0.579). Similarly, no statisti-
cally significant difference was found between the CO
exposed group and control group regarding pulmonary
NEBs (Fig. 3B), although the number of NEBs located
both in the alveolobronchiolar (1.7 ± 0.3 cells/cm2 ver-
sus 1.8 ± 0.6 cells/cm2, p = 0.837) and bronchial
(1.9 ± 0.1 cells/cm2 versus 2.1 ± 0.3 cells/cm2,
p = 0.530) area were fewer in the CO exposed group than
in the control group. Interestingly, the number of alveolo-
bronchial NEBs was nearly equal to the number of NEBs
located in the airway epithelium, independent of the
exposure group. No difference between CO exposed and
control animals was seen regarding the size of the aNEBs
(5.6 ± 0.6 cells versus 5.2 ± 0.7 cells, p = 0.696) or
bNEBs (7.0 ± 0.5 cells versus 7.1 ± 0.5 cells, p = 0.902).
3.4. Effects of CO on the cardiovascular system
3.4.1. Cardiac weights
Chronic CO exposure for 72 weeks induced a 20%
(p = 0.001) increase in RV weight and a 14% (p < 0.001)
increase in LV + S weight compared to control animals
(Table 2). The same trend was seen after only 6 months
of exposure, where analysis of some animals showed an
increase in LV + S weight in the CO exposed versus the
Hb (g/dl)
CO exposed n Control n
13.7 ± 0.2 8 13.2 ± 0.2 8
– –
14.5 ± 0.6* 16 13.4 ± 0.3 8
15.0 ± 0.9 4 11.8 ± 0.2 2
14.7 ± 0.1* 43 13.1 ± 0.2 22
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Fig. 2. Electron micrograph of the alveolar wall showing no differences between CO exposed and control rats. (A) Capillary vessel with an electron
d d rat. (B
a ctively.
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ir at higher magnification from a CO exposed and a control rat, respe
nd the pneumocyte with a fused basal membrane between.
ontrol group (556 ± 33 mg versus 510 ± 14 mg, n = 4
ersus 2, respectively).
.4.2. Cardiac morphology
No macroscopic differences of the heart were
bserved between the study groups. Furthermore, no
istopathologic changes like oedema, inflammation, or
igns of scarring were observed in H&E stained sections
f the right and left ventricular wall.
.4.3. Pulmonary arteries
H&E stained sections of the lung showed no struc-
ural signs of hypertension in the arteries. In addition, no
ifferences in proportion of small muscularized arter-
es to non-muscularized arteries were observed between
O exposed and control animals (47.9 ± 2.3% versus
7.6 ± 1.9%, p = 0.936) in Elastica van Gieson stained
ections.
.4.4. Systemic arteries
H&E stained cross sections of the femoral artery andhree sections of the distal part of the thoracic aorta
howed no signs of atherosclerotic lesions in the CO
xposed group. In the control group, only one of 15
xamined animals showed a plaque-like lesion in theand C) The gaseous diffusion barrier between blood and the alveolar
The barrier consists of a thin cytoplasmic layer of the endothelial cell
femoral artery with thickening of the lamina interna. No
abnormality was observed in the thoracic aorta in the
control group.
3.5. Tumourigenesis
The location and type of tumours observed are sum-
marised in Table 4. In both groups, tumours of the ante-
rior pituitary gland were the most frequent neoplasia,
observed in 12 and 16% of the CO exposed and control
animals, respectively. These tumours were all classified
as benign adenomas, with a NE morphology without
atypia and with a low rate of mitosis. One of the tumours
measured 1 cm in diameter, causing compression of nor-
mal cerebral tissue and neurological symptoms with gait
disturbance. Tumours of the mammary gland were only
observed in the CO exposed group. Only one of the
tumours (an adenocarcinoma of the uterus) was asso-
ciated with metastasis. In the lungs, no macroscopic
tumours were seen. Microscopic examination revealed
one small tumour, exhibiting adenocarcinoma charac-
teristics, in the CO exposed group. Using immunohisto-
chemistry one NE hyperplastic lesion was found both in
the CO exposed and control group (Fig. 3C). This hyper-
plasia of NE cells into small tumour-like lesions <0.5 cm
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Fig. 3. Histological findings in the lungs. Immunohistochemical reactivity for CGRP visualising two single PNEC (A) and a NEB (B) among
lastic le
ng normepithelial cells in a bronchus from a CO exposed rat. (C) NE hyperp
Heamatoxylin and eosin stained section from a CO exposed rat showi
follicle.
in diameter seems to resemble the human parallel named
tumourlets, except their papillary appearance in the rats.
The proportion of total number of animals with tumours
did not differ significantly between the groups (29%
versus 28%, p = 0.959). Only one of the animals (CO
exposed) died spontaneously during the exposure period,
suffering from leukaemia. In addition, two CO exposed
rats were sacrificed after 15 and 17 months, respectively,
and one control rat after 17 months, because of signs of
illness (Table 5). Examination of the animals revealed a
large mammary tumour, an adenocarcinoma of the ovary
and a pituitary adenoma, respectively.4. Discussion
The present work reports an inhalation study of CO
on rats, at doses comparable to tobacco smoking with ansion immunoreactive for CGRP in an airway from a control rat. (D)
al alveolar parenchyma and a bronchiole associated with a lymphoid
exposure time of three quarters of their life expectancy.
Except for cardiac hypertrophy, no structural changes in
the respiratory and cardiovascular system were observed.
Furthermore, no tumourigenic effect of CO exposure
was seen. To our knowledge, few long-term experimen-
tal studies of low level CO exposure have been pub-
lished (Stupfel and Bouley, 1970; Armitage et al., 1976;
Turner et al., 1979). Compared to previous studies, with a
CO concentration ≤250 ppm and an exposure time >12
months, this study adds important information regard-
ing the morphology of the respiratory system, including
pulmonary NE cells in chronic CO exposed animals.
Chronic CO exposure does not appear to induce
morphological changes in the lungs. The respiratory
pathology usually associated with cigarette smoking
was absent in the current study. To our knowledge, no
detailed information of the respiratory morphology from
S. Sørhaug et al. / Toxicology
Table 4
Number of animals with tumours
Tumours (site and type) CO exposed
(n = 49)
Control
(n = 25)
Pituitary gland
Adenoma 6 (12%) 4 (16%)
Mammary gland
Fibroadenoma 3 0
Ovary
Adenocarcinoma 1 0
Haemangioma 0 1
Uterus
Leiomyoma 1 0
Salivary gland
Adenocarcinoma 0 1
Haematopoietic system
Leukaemia 1 0
Liver
Metastasis from
adenocarcinoma of
the uterus
1 0
Lung
Adenocarcinoma 1 0
Tumourlets/NE
hyperplasia
1 1
Total number of animals 14 (29%) 7 (28%)
D
l
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e
T
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T
2
2
6
6
7
Dwith tumours
ata are presented as n, numbers and % of each group.
ong-term CO exposure exists. In a short-term, study by
ugod (1980), no morphological changes were observed
n the lungs of adult rabbits exposed to 200 ppm for
p to 6 weeks. Another study of CO exposure to rats
250–1300 ppm) for 7.5 weeks showed an increase in
ung weight, which was not due to increase in blood
olume in the lung, oedema or fibrosis (Penney et al.,
988). However, our study did not confirm this finding,
ven after near life-time exposure.
able 5
umber of withdrawal rats during the exposure period
ime (weeks) CO exposed
Withdrawal
(planned)
Withdrawal
(illness)
Remaining
animals
0 51
2 2 49
0 1 48
4 4 44
0 1 43
8 1 42
2 42
ata are presented as numbers.228 (2006) 280–290 287
Changes in the pulmonary NE system with hyperpla-
sia of the PNEC/NEBs have been described in suscepti-
ble smokers and diseases associated with tobacco smok-
ing (Gosney et al., 1989; Aguayo, 1993). The mechanism
for this response is unknown, but one proposed hypoth-
esis is that components of tobacco smoke may stimulate
NE cells to proliferate (Novak et al., 1999). In addition,
experimental studies have shown an increase in number
of PNEC/NEBs in response to chronic high concen-
tration of gases like oxygen and ozone or non-filtrated
urban ambient air (Schuller et al., 1988; Ito et al., 1989,
1994). It has been proposed that NEBs are acting as
an oxygen sensor through a membrane bound heme-
protein (Youngson et al., 1993; Cutz and Jackson, 1999).
The oxygen molecule is bound to the heme-containing
membrane receptor (NADPH-oxidase), where decreas-
ing oxygen levels lead to depolarisation and secretion
of bioactive substances (Kemp et al., 2002). Secreted
peptides or amines may further act as auto or paracrine
mediators, like CGRP which has a growth stimulating
effect.
Similar to the binding of CO to the heme of
haemoglobin, it is postulated that CO may bind to the
NADPH-oxidase (Haddad, 2002). To our knowledge, no
experimental studies have been published, reporting the
effects of CO exposure on the pulmonary NE system. The
immunohistological results of the present study exhibit
a trend of increased single PNEC and a lower number of
NEBs in the CO exposed group, although changes were
not statistically significant. We conclude that chronic CO
inhalation does not significantly affect the pulmonary
NE system in a way detectable by current morphologi-
cal evaluation.
The carcinogenic effect of tobacco smoke is well
known. Recent epidemiological studies have shown an
association between cigarette smoking and cancers of
the lung, urinary tract, aerodigestive tract, larynx, pan-
creas, stomach, liver, kidney, uterine cervix and myeloid
Control
Withdrawal
(planned)
Withdrawal
(illness)
Remaining animals
26
1 25
25
2 23
23
1 22
22
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leukaemia (Mauderly et al., 2004; Sasco et al., 2004).
In our study, we found a tumour at the time of sacri-
fice in nearly 1/3 of the animals, independent of CO
exposure. This rate of spontaneous tumours is similar to
that reported in elderly rats from previous studies and
indicate that long-term inhalation of CO does not have
tumourigenic effects (Stupfel and Bouley, 1970; Kroes
et al., 1981; Waldum et al., 1994).
In recent years, several studies have focused on
the possible beneficial physiological and cytoprotective
effects of low dose CO. CO is produced endogenously in
human tissues through breakdown of heme by heme oxy-
genase (HO), releasing iron and CO (Omaye, 2002). Dur-
ing conditions like hypoxia or inflammation, increased
levels of HO, and thereby CO, have been found. CO is
regarded as a cellular signal molecule in normal phys-
iology, and may act as a neurotransmitter, vasodilator,
bronchodilator and inhibitor of platelet function (for
review, see Sethi, 2005; Kim et al., 2006). In addition, it
may exert a protective role in a wide variety of diseases,
with its anti-inflammatory and anti-proliferative effects
(Ryter and Otterbein, 2004). Some recent in vivo studies
have shown the cytoprotective effects of low-dose CO in
acute lung injury, lung fibrosis and vascular transplants
(Otterbein et al., 1999; Sato et al., 2001; Zhou et al.,
2005). Our study was not designed to investigate possible
protective effects on pathological processes. However,
for future therapeutic considerations, the present work
may support the safety of low dose CO inhalation on the
respiratory system.
Current evidence for a role of CO in cardiovas-
cular diseases is inconsistent. Some previous studies
have linked CO exposure to the process of atheroscle-
rosis and coronary artery diseases. Astrup et al. (1967)
found cholesterol and lipid deposits in the aortic wall
of rabbits, induced by several months of CO exposure
at COHb levels of 20–33%. In addition, in vitro stud-
ies of blood platelets exposed to CO at concentrations
of 50–100 ppm, displayed an increase in released nitric
oxide-derived oxidants, which may damage the vascular
endothelium (Thom and Ischiropoulos, 1997). However,
only a few experimental studies have investigated long-
term CO exposure covering most of the animals’ life-
time. A study by Stupfel and Bouley (1970) reported
no pathological changes in the aorta of rats exposed to
50 ppm CO for up to 2 years. In contrast to this, an
exposure study of white Carneau pigeons, fed a high
cholesterol diet for 52 weeks, resulted in enhanced coro-
nary artery lesion development in those pigeons exposed
to 150 ppm CO (Turner et al., 1979). The present study,
with near life-long exposure and COHb level equal to
heavy smokers, revealed no significant pathology indi-228 (2006) 280–290
cating atherosclerosis in the aorta or the systemic femoral
artery. It must be noted that, unlike some previous stud-
ies, the rats in our study were fed a standard rodent pellet
diet not enriched with lipids or cholesterol for only 4 h
a day, 5 days a week, with free access during weekends.
This may have delayed the onset of the atherosclerotic
process, but is probably a more representative physiolog-
ically model than a lipid-rich diet. Altogether, our find-
ings support the hypothesis that chronic CO inhalation
has no atherogenic effect in animals fed normal diets.
The finding of increased cardiac weight in long-term
CO exposed animals is consistent with previous stud-
ies, even with a shorter exposure time than used in our
study (Penney et al., 1982, 1984; Clubb et al., 1986).
In addition, a recent study of experimental myocardial
infarction in rats showed an increase in infarct size and
worsening of heart failure, but also remodelling of the
ventricles with myocardial hypertrophy of the oppo-
site wall (Mirza et al., 2005). However, inconsistent
data exists concerning the relationship between right
and left ventricular hypertrophy (Penney et al., 1984;
Loennechen et al., 1998). The present study shows that
the weight of both ventricles increased, since the ratio
RV/(LV + S) was similar in CO exposed and control ani-
mals. The reasons for CO-induced cardiac hypertrophy
are not completely known. It appears that cardiac hyper-
trophy develops in spite of the CO-induced lowering
of systemic blood pressure and thereby lowering LV
afterload (Penney and Formolo, 1993). One hypothesis
is that ventricular hypertrophy results from an increase
in volume overload due to blood volume and viscosity
enhancement and increased ventricular preload. How-
ever, mechanisms other than increased work load or
haemodynamic effects may by postulated. Our find-
ings, indicating a complete absence of pulmonary arterial
hypertension and hypertrophy of both ventricles, support
the idea of a possible intrinsic effect on the myocardium
mediated by CO. At present, the exact pathways involved
are unknown.
The current findings of an apparent safety of CO
inhalation at doses of 200 ppm regarding to tumouri-
genesis, the respiratory organs and cardiovascular sys-
tem, except cardiac hypertrophy, may be applied to
only healthy adult rats. Other studies have shown that
effects of CO on pathological conditions in rats may
include both detrimental effects, like increased infarct
size (Mirza et al., 2005), but also favourable effects
like cytoprotection in acute lung disease (Otterbein et
al., 1999). Furthermore, studies have described sev-
eral effects on developing rats (Stockard-Sullivan et
al., 2003). In addition, even though some physiological
mechanisms are conserved, there may be species dif-
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erences. In some recent studies, the anti-inflammatory
ffects of inhaled CO observed in a mouse model, could
ot be detected in a comparable human model (Mayr et
l., 2005). This shows that the findings have to be inter-
reted with caution when applied to humans.
In conclusion, long-term CO inhalation in rats at lev-
ls corresponding to tobacco smoking, induces right
nd left ventricular hypertrophy, but not increased
therosclerosis. CO exposure is not associated with
obacco smoking related pathology of the respiratory
ystem, and has no impact on the morphology of pul-
onary NE cells or tumourigenesis.
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